CA2389117A1 - Methods and compositions for enhancing developmental potential of oocytes and zygotes - Google Patents
Methods and compositions for enhancing developmental potential of oocytes and zygotes Download PDFInfo
- Publication number
- CA2389117A1 CA2389117A1 CA002389117A CA2389117A CA2389117A1 CA 2389117 A1 CA2389117 A1 CA 2389117A1 CA 002389117 A CA002389117 A CA 002389117A CA 2389117 A CA2389117 A CA 2389117A CA 2389117 A1 CA2389117 A1 CA 2389117A1
- Authority
- CA
- Canada
- Prior art keywords
- mitochondria
- replicative
- oocytes
- donor cell
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000287 oocyte Anatomy 0.000 title claims abstract description 157
- 238000000034 method Methods 0.000 title claims abstract description 105
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 210000003470 mitochondria Anatomy 0.000 claims abstract description 198
- 230000003362 replicative effect Effects 0.000 claims abstract description 77
- 238000012546 transfer Methods 0.000 claims abstract description 55
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 36
- 238000000338 in vitro Methods 0.000 claims abstract description 26
- 230000001965 increasing effect Effects 0.000 claims abstract description 25
- 230000037041 intracellular level Effects 0.000 claims abstract description 16
- 230000004720 fertilization Effects 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 86
- 241000894007 species Species 0.000 claims description 31
- 210000002257 embryonic structure Anatomy 0.000 claims description 28
- 210000003855 cell nucleus Anatomy 0.000 claims description 24
- 210000000130 stem cell Anatomy 0.000 claims description 23
- 108020005196 Mitochondrial DNA Proteins 0.000 claims description 15
- 210000004940 nucleus Anatomy 0.000 claims description 15
- 230000013020 embryo development Effects 0.000 claims description 14
- 230000035772 mutation Effects 0.000 claims description 14
- 230000037430 deletion Effects 0.000 claims description 13
- 238000012217 deletion Methods 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 11
- 230000001850 reproductive effect Effects 0.000 claims description 9
- 230000009946 DNA mutation Effects 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- 210000003754 fetus Anatomy 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 5
- 230000001086 cytosolic effect Effects 0.000 claims description 5
- 230000007159 enucleation Effects 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 238000000520 microinjection Methods 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 210000001109 blastomere Anatomy 0.000 claims description 4
- 230000001627 detrimental effect Effects 0.000 claims description 4
- 230000031864 metaphase Effects 0.000 claims description 4
- 241000283073 Equus caballus Species 0.000 claims description 3
- 210000004291 uterus Anatomy 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 210000001612 chondrocyte Anatomy 0.000 claims description 2
- 210000003981 ectoderm Anatomy 0.000 claims description 2
- 210000001900 endoderm Anatomy 0.000 claims description 2
- 210000001339 epidermal cell Anatomy 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 210000002510 keratinocyte Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 210000002752 melanocyte Anatomy 0.000 claims description 2
- 210000003716 mesoderm Anatomy 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 210000000663 muscle cell Anatomy 0.000 claims description 2
- 210000003061 neural cell Anatomy 0.000 claims description 2
- 230000010627 oxidative phosphorylation Effects 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 210000003708 urethra Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 210000002459 blastocyst Anatomy 0.000 description 16
- 238000013467 fragmentation Methods 0.000 description 16
- 238000006062 fragmentation reaction Methods 0.000 description 16
- 238000011161 development Methods 0.000 description 15
- 230000018109 developmental process Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 230000030833 cell death Effects 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 230000006907 apoptotic process Effects 0.000 description 11
- 230000035935 pregnancy Effects 0.000 description 9
- 210000000805 cytoplasm Anatomy 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 7
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000008774 maternal effect Effects 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 210000001082 somatic cell Anatomy 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010052641 Mitochondrial DNA mutation Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 231100000182 Sperm DNA damage Toxicity 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229960002756 azacitidine Drugs 0.000 description 3
- 230000006721 cell death pathway Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 210000001771 cumulus cell Anatomy 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229940012982 picot Drugs 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 231100000167 toxic agent Toxicity 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 241001550206 Colla Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 2
- 208000035752 Live birth Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 229940094892 gonadotropins Drugs 0.000 description 2
- 210000002503 granulosa cell Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000893 inhibin Substances 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000010449 nuclear transplantation Methods 0.000 description 2
- 210000004508 polar body Anatomy 0.000 description 2
- 230000000270 postfertilization Effects 0.000 description 2
- 230000001012 protector Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- PYTMYKVIJXPNBD-OQKDUQJOSA-N 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-OQKDUQJOSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- -1 FSH Chemical compound 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
- 208000009564 MELAS Syndrome Diseases 0.000 description 1
- 201000009035 MERRF syndrome Diseases 0.000 description 1
- 108010057021 Menotropins Proteins 0.000 description 1
- 206010051403 Mitochondrial DNA deletion Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
- 206010069825 Myoclonic epilepsy and ragged-red fibres Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 208000001300 Perinatal Death Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241001665167 Solter Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000034790 Twin pregnancy Diseases 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 101100082060 Xenopus laevis pou5f1.1 gene Proteins 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000000625 blastula Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000244 chromosomal damage Toxicity 0.000 description 1
- 229940046989 clomiphene citrate Drugs 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 230000000959 cryoprotective effect Effects 0.000 description 1
- 239000008150 cryoprotective solution Substances 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000009547 development abnormality Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000001733 follicular fluid Anatomy 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003772 granulosa lutein cell Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000034004 oogenesis Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000007542 postnatal development Effects 0.000 description 1
- 230000009237 prenatal development Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000538 tail Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001573 trophoblastic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to compositions and methods for enhancing the developmental potential of oocytes or zygotes by increasing intracellular levels of replicative mitochondria in the oocytes or zygotes. In one aspect of the invention, the intracellular levels of replicative mitochondria are increased by introducing replicative mitochondria into the oocytes or zygotes.
The oocytes may be fertilized to obtain a zygote with increased intracellular levels of replicative mitochondria. The methods and compositions may be used to improve in vitro fertilization and embryo transfer methods, and nuclear transfer techniques.
The oocytes may be fertilized to obtain a zygote with increased intracellular levels of replicative mitochondria. The methods and compositions may be used to improve in vitro fertilization and embryo transfer methods, and nuclear transfer techniques.
Description
T~fTLE: Methods and Compositions for Enhancing Developmental Potential of Oocytes and Zygotes FIELD OF THE INVENTION
The invention relates to compositions and methods for enhancing the developmental potential of oocytes, zygotes, and preimplantation embryos.
BACKGROUND OF THE INVENTION
With in vitro fertilization (IVF) and other assisted reproductive technologies, about 50% of human embryos undergo a suicide program of active cell death and become fragmented. Some infertility patients produce only fragmented embryos, which appears to be the cause of their failure to conceive or carry a pregnancy to term.
In all mammals, including humans, zygote development and the first cleavage divisions depend upon maternal RNA and protein products accumulated during oogenesis.
Reproductive failure can be attributed to the lack of cleavage in the developing embryo. This phenomenon can be traced to a defect in the composition of the oocyte cytoplasm. Maternal cytoplasmic components are involved in embryonic arrest, because the "2-cell block" in mice can be overcome by transplantation of ooplasm from zygotes of non-arresting strains into the zygotes of arresting strains (Muggleton-Hams et al, Nature. 1982 Sep 30;299 (5882):460-2). Similar oocyte cytoplasm transfer experiments demonstrated improvement in the developmental capacity of immature eggs in mice (Flood et al., 1990). Later, Cohen and colleagues obtained a pregnancy in a patient with a history of consistently fragmented 2 0 embryos by transfer of donor oocyte cytoplasm into the patient's oocytes at the time of intracytoplasmic sperm injection (Cohen et al., Lancet, 1997 Jul 19;350(9072):186-7). More recently, Lanzendorf et al. (Fertil Steril. 1999 Mar;71(3):575-7) demonstrated that frozen-thawed oocyte cytoplasm microinjected into oocytes, improved their developmental competency after fertilization, and resulted in a twin pregnancy in a patient who previously produced only fragmented embryos.
2 5 Nuclear transfer as a means of producing identical individuals (clones) has been successfully performed in several mammalian species including goat, sheep, pig, cattle, and mice. In all of these cases, efficiency of this technique is very low. While development of reconstituted embryos to the blastocyst stage is moderate (~40%, Ogura et al, 2000 Biol. Reprod. 62(6):1579-84, 2000; Mol.
Reprod. Development 57:55-59, 2000), live birth rate is unexpectedly low ( 1-7%, Ogura et al, 2000, 3 0 supra, Polejaeva et al Nature 2000 Sep 7;407(6800):86-90). Moreover, extensive fetal and early neonatal death has previously been reported in offspring obtained by nuclear transfer (Rideout WM
3rd, Wakayama T, Wutz A, Eggan K et al 2000 Nat Genet Feb;24(2):109-10).
Thus, there is a need to enhance the developmental potential of oocytes to improve reproductive technologies including nuclear transfer methods.
The invention relates to a method for enhancing developmental potential of oocytes comprising increasing intracellular levels of replicative mitochondria in the oocytes. In an embodiment _2_ of the invention, the intracellular levels of replicative mitochondria are increased by introducing replicative mitochondria into the oocytes. A method of the invention may additionally comprise fertilizing the oocytes to obtain a zygote with increased intracellular levels of replicative mitochondria.
The invention also relates to a method for enhancing developmental potential of zygotes comprising increasing intracellular levels of replicative mitochondria in the zygotes. In an embodiment of the invention, the intracellular levels of replicative mitochondria are increased by introducing replicative mitochondria into zygotes.
The invention further relates to an oocyte or a zygote with increased intracellular levels of replicative mitochondria obtained from a method of the invention.
In a further aspect the invention relates to a composition comprising replicative mitochondria for enhancing developmental potential of oocytes or zygotes, and for treating and preventing heritable mitochondria) diseases. The composition may comprise cryopreserved mitochondria.
In another aspect, the invention provides a method for fertilizing oocytes comprising removing oocytes from a follicle of an ovary, introducing replicative mitochrondria into the oocytes, and fertilizing the resulting oocytes with spermatozoa.
In a still further aspect the invention provides a method for storing and then enhancing the developmental potential of oocytes comprising cryopreserving immature oocytes, thawing the cryopreserved oocytes, and introducing replicative mitochondria into the oocytes. A method is also contemplated for enhancing the developmental potential of oocytes comprising cryopreserving 2 0 replicative mitochondria, thawing the mitochondria, and introducing the replicative mitochondria into oocytes.
The methods and compositions of the invention improve the quality of the oocytes that are being fertilized and the quality of zygotes, to increase the rate of success in embryo development and ongoing pregnancy. The methods and compositions are particularly useful in enhancing the 2 5 developmental potential of oocytes or zygotes with mitochondria) DNA
mutations or abnormal mitochondria) metabolic activity.
In an aspect, the invention provides a method for improving embryo development after in vitro fertilization or embryo transfer in a female mammal comprising implanting into the female mammal an embryo derived from an ooctye or zygote containing increased intracellular levels of 3 0 replicative mitochondria.
The invention also provides a method for reducing the detrimental effects of mitochondria) DNA mutations (e.g. deletion or missense mutations) in the progeny of an individual affected by such mutations comprising introducing into oocytes or zygotes from the individual replicative mitochondria that does not contain the DNA mutations (i.e. healthy mitochondria). The invention further provides 3 5 an oocyte or a zygote comprising both mitochondria with mitochondria) DNA
mutations, and purified and isolated replicative mitochondria that do not contain the mitochondria) DNA mutations (i.e. healthy mitochondria).
The invention also relates to a method for treating heritable mitochondria) diseases in the progeny of an individual affected by such diseases comprising introducing into oocytes or zygotes from the individual replicative mitochondria comprising mitochondria that does not contain the DNA
mutations (i.e. healthy mitochondria).
In an aspect of the invention, the oocyte is a recipient ooctye in a nuclear transfer method.
Thus, the invention relates to a method for enhaincing developmental potential of recipient oocytes in a nuclear transfer method comprising introducing replicative mitochondria into the recipient oocytes.
The invention also contemplates recipient oocytes comprising replicative mitochondria, and blastocyts, embryos, and non-human animals formed from the nuclear transfer methods of the invention. In conventional nuclear transfer methods, the donor nucleus is placed in an enucleated oocyte obtained from a different individual. Thus, mitochondria in the recipient oocyte have not-co-existed with the donor nucleus. Since mitochondria are always maternally inherited, their replication, transcription, ttanslation, and function does not only depend on mitochondria) DNA, but is tightly intercalated with the nuclear genome that co-exists with the mitochrondria. The invention by introducing replicative mitochondria into recipient oocytes enhances the developmental potential of the recipient oocytes. This is expected to increase the live birth rate in nuclear transfer methods.
In an embodiment, the invention provides a method of cloning a non-human mammalian embryo by nuclear transfer comprising (a) introducing a donor cell nucleus derived from a donor cell of a non-human mammal, and 2 0 replicative mitochondria preferably from the same species as the donor cell, more preferably from the same species and cell type as the donor cell, most preferably from the non-human mammal from which the donor cell nucleus is derived, into an enucleated recipient oocyte of the same species as the donor cell to form a nuclear transfer unit, (b) culturing the nuclear transfer unit to form an embryo.
2 5 The method may further comprise permitting the embryo to develop into a cloned mammal.
Therefore, the invention also provides a method of cloning a non-human mammal by nuclear transfer comprising (a) introducing a donor cell nucleus derived from a donor cell of a non-human mammal, and replicative mitochondria preferably from the same species as the donor cell, more preferably 3 0 from the same species and cell type as the donor cell, most preferably from the non-human mammal from which the donor cell nucleus is derived, into a non-human mammalian enucleated recipient oocyte of the same species as the donor cell to form a nuclear transfer unit, (b) culturing the nuclear transfer unit to form an embryo;
3 5 (c) implanting the embryo into the uterus of a surrogate mother of said species, and (d) permitting the embryo to develop into the cloned mammal.
In yet another embodiment, a method of cloning a non-human mammalian fetus by nuclear transfer is provided comprising the following steps:
(a) introducing a donor cell nucleus from a donor cell of a non-human mammal, and replicative mitochondria preferably from the same species as the donor cell, more preferably from the same species and cell type as the donor cell, most preferably from the non-human mammal from which the donor cell nucleus is derived, into an enucleated recipient oocyte of the same species as the donor cell to form a nuclear transfer unit, (b) culturing the nuclear transfer unit until greater than the 2-cell developmental stage; and (c) transferring the cultured nuclear transfer unit to a host non-human mammal of the same species such that the nuclear transfer unit develops into a fetus.
The method may also comprise developing the fetus into an offspring.
In a further aspect the invention provides a recipient oocyte comprising a perivitelline space and a donor cell nucleus and replicative mitochondria preferably from the same species as the donor cell, more preferably from the same species and cell type as the donor cell, most preferably from the same individual from which the donor cell nucleus is dervied, deposited in the perivitelline space.
Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention 2 0 will become apparent to those skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a bar graph showing the effect of mitochondria injection on preimplantaion embryo development.
DETAILED DESCRIPTION OF THE INVENTION
2 5 The term "oocytes" refers to the gamete from the follicle of a female animal, whether vertebrate or invertebrate. Preferably, the animal is a mammal, and more preferably is a non-human primate, a bovine, equine, porcine, ovine, caprine, buffalo, guinea pig, hamster, rabbit, mice, rat, dog, cat, or a human. Suitable oocytes for use in the invention include immature oocytes, and mature oocytes from ovaries stimulated by administering to the oocyte donor, in vitro or in vivo, a fertility 3 0 agent or fertility enhancing agent (e.g. inhibin, inhibin and activin, clomiphene citrate, human menopausal gonadotropins including FSH, or a mixture of FSH and LH, and/or human chorionic gonadotropins). In some embodiments of the invention, the oocytes are aged (e.g. from humans 40 years +, or from animals past their reproductive prime). The oocytes in some embodiments of the invention contain mitochondrial DNA mutations. Methods for isolating oocytes are known in the art.
3 5 In the nuclear transfer embodiments of the invention oocytes are used as recipient cells (such cells are referred to herein as "recipient oocytes"). The recipient ooctyes are obtained from non-human mammals, in particular domestic, sports, zoo, and pet animals including but not limited to bovine, ovine, porcine, equine, caprine, buffalo, and guinea pigs, rabbits, mice, hamsters, rats, primates, etc.
The term "zygote" refers to a fertilized oocyte prior to the first cleavage division.
The expression "enhancing the developmental potential of oocytes" refers to increasing the quality of the oocyte so that it will be more capable of being fertilized and/or enhancing mitochondria) function or activity in the oocyte for subsequent development and reproduction. Increasing the quality of the oocyte, and thus the fertilized oocyte (e.g. zygote), preferably results in enhanced development of the oocyte into an embryo and its ability to be implanted and form a healthy pregnancy. The expression "enhancing the developmental potential of zygotes" refers to increasing the quality of the zygotes and/or enhancing mitochondria) function or activity in the zygotes for subsequent development and reproduction. Increasing the quality of the zygotes, preferably results in enhanced development of the zygotes into an embryo and their ability to be implanted and form a healthy pregnancy. Quality can be assessed by the appearance of the developing embryo by visual means and by the IVF or nuclear transfer success rate. Criteria to judge quality of the developing embryo by visual means include, for example, their shape, rate of cell division, fragmentation, appearance of cytoplasm, and other means recognized in the art of IVF and nuclear transfer.
"Spermatozoa" refers to male gametes that can be used to fertilize oocytes.
"Heritable mitochondria) diseases" refers to diseases caused by defects in mitochondria) DNA or by defects in nuclear genes that are important to mitochondria) function. Examples of mitochondria) diseases include but are not limited to Kearns-Sayre syndrome, MERRF syndrome 2 0 (Myoclonic Epilepsy with Ragged Red Fibres), MELAS syndrome (Mitochondria) Encephalopathy, Myopathy, Lactic Acidosis and Stroke-like episodes), and Leber's disease (I.
Nonaka, Current Opinion in Neurology and Neurosurgery, 5 ( 1992) 622).
The term "replicative microchondria" refers to a preparation of purified mitochondria that are capable of replicating during embryo development and increasing mitochondria) copy number or 2 5 function. The replicative mitochondria is substantially free of other cytoplasmic components including nuclear DNA, mRNA, proteins, antioxidants, and organelles other than mitochondria. The replicative mitochondria preparations are at least 60% free, preferably 75% free, and most preferably 90% free from other cytoplasmic components. Preferably the replicative mitochondria preparations contain greater than 70%, more preferably greater than 80%, most preferably greater than 90% functional 3 0 mitochondria. A replicative mitochondria preparation typically contains about 2,000 to 20,000 mitochondria in a volume of 5 to 15 picot.
For the non-nuclear-transfer embodiments of the invention, replicative mitochondria are preferably derived from any stem cell (e.g. hematopoietic, embryonic, trophoblastic, primordial germ cells) or from any immortalized cell line (e.g. cancer, or intentionally transformed somatic cells) of any 3 5 species, preferably human. The cells are preferably free of the common mitochondria) deletion mutation found clinically in patients with KSS syndrome (i.e. deleted 4799bp region at tit 8470-13,447;
see Simonnetti et al, 1992) and any other pathologic mitochondria) DNA
mutation. Particular methods for preparing replicative mitochondria are illustrated herein and are described in Darley-Usmer VM., Rickwood D, Willson MT. Mitochondria, a Practical Approach, Oxford Washington DC., IRL Press, 1987, pp. 1-16.
Stem cells used to prepare the replicative mitochondria can be genetically modified by genetic engineering techniques. A transgene may be introduced into the cells via conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, or microinjection. Suitable methods for transforming and transfecting cells can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory textbooks. (See also Nolta et al Blood. 1995 Jul 1;86(1):101-10; and Nolta et al Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2414-9; and Kohn et al Nat Med. 1998 Jul;4(7):775-80.). By way of example, a transgene may be introduced into cells using an appropriate expression vector including but not limited to cosmids, plasmids, or modified viruses (e.g. replication defective retroviruses, adenoviruses and adeno-associated viruses). Transfection is easily and efficiently obtained using standard methods including culturing the cells on a monolayer of virus-producing cells (Van der Putten, Proc Natl Acad Sci U S A. 1985 Sep;82(18):6148-52; Stewart et al. ( 1987) EMBO J. 6:383-388). Examples of genes that may be introduced into the stem cells include genes encoding cell death protectors such as Bcl-xL and McL-1.
Cryoprotective methods can be used to maintain maximum viability of the replicative mitochondria. Cryopreservation can be carried out in a medium containing for example 2 0 dimethylsulphoxide, ethylene glycol, or glycerol or sucrose with 1,2-propanediol, or the mitochondria can be vitrified using cryoprotectants such as ethylene glycol and dimethyl sulphoxide. In an embodiment of the invention, the cryopreservation procedure involves cooling the mitochondria in a cryoprotective solution to an appropriate temperature (e.g. -176°).
Scanning and transmission electron microscopy can be used to assess the purity and 2 5 morphology of a preparation. In addition the preparation can be analyzed for membrane mitochondrial potential and the total number and concentration of functional mitochondria present can be determined in accordance with conventional methods as described herein. Replicative ability of the mitochondria in a preparation can be determined using conventional techniques including restriction fragment polymorphism methods as described herein.
3 0 The present invention generally involves the use of replicative mitochondria to enhance the developmental potential of animal oocytes, especially mammals, including sports, zoo, pet, and farm animals, in particular dogs, cats, cattle, pigs, horses, goats, buffalo, rodents (e.g. mice, rats, guinea pigs), monkeys, sheep, and humans. In the nuclear transfer methods, replicative mitochondria are used to enhance the developmental potential of non-human recipient oocytes.
3 5 A method of the invention involves removing the oocytes from follicles in the ovary. This can be accomplished by conventional methods for example, using the natural cycle, during surgical intervention such as oophorohysterectomy, during hyperstimulation protocols in an IVF program, or _7-by necropsy. Oocyte removal and recovery can be suitably performed using transvaginal ultrasonically guided follicular aspiration.
After oocytes have been isolated, replicative mitochondria are introduced into the oocytes, or the oocytes can be cryopreserved for storage in a gamete or cell bank. If the oocytes are not cryopreserved the oocytes should be treated in accordance with the method of the invention preferably within 48 hours after aspiration. If the oocytes are frozen, they can be thawed when it is desired to use them and treated in accordance with a method of the invention.
Replicative mitochondria may be introduced into the oocytes (or zygotes) by conventional microinjection techniques or by other techniques such as electrofusion of mitochondria contained within liposomes or other suitable means.
After introduction, simultaneously with, or prior to the introduction of the replicative mitochondria, the oocytes are fertilized with suitable spermatozoa from the same species. The fertilization can be carried out by known techniques including sperm injection. Suitable human in vitro fertilization and embryo transfer procedures that can be used include in vitro fertilization (IVF) (Trounson et al. Med J Aust. 1993 Jun 21;158( 12):853-7, Trouson and Leeton, in Edwards and Purdy, eds., Human Conception in Vitro, New York:Academic Press, 1982, Trounson, in Crosignani and Rubin eds., In Vitro Fertilization and Embryo Transfer, p. 315, New York:
Academic Press, 1983);
intracytoplasmic sperm injection (ICSI) (Casper et al., Fertil Steril. 1996 May;65(5):972-6); in vitro fertilization and embryo transfer (IVF-ET)(Quigly et al, Fert. Steril., 38:
678, 1982); gamete 2 0 intrafallopian transfer (GIFT) (Molloy et al, Fertil. Steril. 47: 289, 1987); and pronuclear stage tubal transfer (PROST) (Yovich et al., Fertil. Steril. 45: 851, 1987).
The methods and compositions of the invention can be used to increase the success rate of embryo development. In particular, they can be used to reduce the detrimental effects of mitochondrial DNA mutations (e.g. deletion or missense mutations) or abnormal or deficient mitochondrial function 2 5 in the progeny of an individual affected by such mutations or abnormal or deficient function, by introducing in oocytes or zygotes from the individual replicative mitochondria that comprises healthy mitochondria.
Mitochondrial DNA deletions or mutations usually result in impaired oxidative phosphorylation and clinical pathology related to muscle or neurologic tissues. For example Keams-3 0 Sayre syndrome (KSS) or progressive external ophthalinoplegia is the result of a common 4799 by deletion (Holt et al., Ann Neurol. 1989 Dec;26(6):699-708) and Leber's hereditary optic neuropathy (LHON) is due to a missence mutation in the mtDNA (Wallace et al., Science 242, 1427 (1998)).
Therefore, injecting oocytes from individuals with these conditions with healthy replicative mitochondria, creating heteroplasmy, may prevent the detrimental effect of mtDNA missence or 3 5 deletion mutations in the progeny.
The invention also contemplates improved nuclear transfer methods using replicative mitochondria. Nuclear transfer methods or nuclear transplantation methods are known in the literature _g_ and are described in for example, Campbell et al, Theriogenology, 43:181 (1995); Collas et al, Mol.
Report Dev., 38:264-267 ( 1994); Keefer et al, Biol. Reprod., 50:935-939 ( 1994); Sims et al, Proc. Natl.
Acad. Sci., USA, 90:6143-6147 ( 1993); WO 94/26884; WO 94/24274, WO 90/03432, U.S. Pat. Nos.
4,944,384 and 5,057,420.
Methods for isolation of recipient oocytes suitable for nuclear transfer methods are well known in the art. Generally, the recipeint oocytes are surgically removed from the ovaries or reproductive tract of a mammal, e.g., a bovine. Once the oocytes are isolated they are rinsed and stored in a preparation medium well known to those skilled in the art, for example buffered salt solutions Recipient oocytes must generally be matured in vitro before they may be used as recipient cells for nuclear transfer. This process generally requires collecting immature (prophase I) oocytes from mammalian ovaries, and maturing the oocytes in a maturation medium prior to fertilization or enucleation until the oocyte attains the metaphase II stage. Metaphase II
stage oocytes, which have been matured in vivo, may also be used in nuclear transfer techniques.
Enucleation of the recipient oocytes may be carried out by known methods, such as described in U.S. Pat. No. 4,994,384. For example, metaphase II oocytes may be placed in HECM, optionally containing cytochalasin B, for immediate enucleation, or they may be placed in a suitable medium, (e.g. an embryo culture medium), and then enucleated later, preferably not more than 24 hours later.
Enucleation may be achieved microsurgically using a micropipette to remove the polar body and the adjacent cytoplasm (McGrath and Solter, Science, 220:1300, 1983), or using functional enucleanon 2 0 (see U.S. 5,952,222). The recipient oocytes may be screened to identify those which have been successfully enucleated.
The recipient oocytes may be activated on, or after nuclear transfer using methods known to a person skilled in the art. Suitable methods include culturing at sub-physiological temperatures, applying known activation agents (e.g. penetration by spem~, electrical and chemical shock), increasing 2 5 levels of divalent canons, or reducing phosphorylation of cellular proteins (see U.S. 5, 496,720) .
A nucleus of a donor cell, preferably of the same species as the enucleated oocyte, is introduced into the enucleated recipient oocyte. The donor cell nucleus may be obtained from any mammalian cells. Donor cells may be differentiated mammalian cells derived from mesoderm, endoderm, or ectoderm.. In particular, the donor cell nucleus may be obtained from epithelial cells, 3 0 neural cells, epidermal cells, keratinocytes, hematopoienc cells, melanocytes, chondrocytes, B-lymphocytes, T-lymphocytes, erythrocytes, macrophages, monocytes, fibroblasts, and muscle cells.
Suitable mammalian cells may be obtained from any cell or organ of the body.
The mammalian cells may be obtained from different organs including skin, lung, pancreas, liver, stomach, intestine, heart, reproductive organ, bladder, kidney and urethra.
3 5 The nucleus of the donor cell is preferably membrane-bounded. A donor cell nucleus may consist of an entire blastomere or it may consist of a karyoplast. A
karyoplast is an aspirated cellular subset including a nucleus and a small amount of cytoplasm bounded by a plasma membrane. (See Methods and Success of Nuclear Transplantation in Mammals, A. McLaren, Nature, Volume 109, June 21, 194 for methods for preparing karyoplasts).
Replicative mitochondria is introduced into the enucleated recipient oocyte.
The replicative mitochondria is preferably derived from the same species as the donor cell, more preferably from the same species and cell type as the donor cell, and most preferably from the same individual from which the donor cell nucleus is derived. Methods for preparing replicative mitochondria are described herein.
Donor cells may be propagated, genetically modified, and selected in vitro prior to extracting the nucleus, or the replicative mitochondria.
The nucleus of a donor cell and/or the replicative mitochondria may be introduced into an enucleated recipient oocyte using micromanipulation or micro-surgical techniques known in the art (see McGrath and Softer, supra). For example, the nucleus of a donor cell may be transferred to the enucleated recipient oocyte by depositing an aspirated blastomere or karyoplast under the zona pellucida so that its membrane abutts the plasma membrane of the recipient oocyte. This may be accomplished using a transfer pipette. Similar methods may be used to introduce the replicative mitochondria.
Fusion of the donor nucleus and the enucleated oocyte may be accomplished according to methods known in the art. For example, fusion may be aided or induced with viral agents, chemical agents, or electro-induced. Electrofusion involves providing a pulse of electricity sufficient to cause a transient breakdown of the plasma membrane. (See U.S. 4, 994,384). In some cases (e.g. with small 2 0 donor nuclei) it may be preferable to inject the nucleus directly into the oocyte rather than using electroporation fusion. Such techniques are disclosed in Collas and Barnes, Mol. Reprod. Dev., 38:264-267 (1994).
The clones produced using the nuclear transfer methods as described herein may be cultured either in vivo (e.g. in sheep oviducts) or in vitro (e.g. in suitable culture medium) to the morula or 2 5 blastula stage. The resulting embryos may then be transplanted into the uteri of a suitable animal at a suitable stage of estrus using methods known to those skilled in the art. A
percentage of the transplants will initiate pregnancies in the surrogate animals. The offspring will be genetically identical where the donor cells are from a single embryo or a clone of the embryo.
The following non-limiting examples are illustrative of the present invention:
3 0 Ezample 1 Injection of a mitochondria) fraction obtained from a human myeloid cell line (HL-60) accelerated and/or facilitated preimplantation embryonic development. Murine zygotes were microinjected with either a mitochondria) fraction or a buffer at day 0.5 and further cultured in vitro until day 3.5. Embryos receiving mitochondria were twice as likely to form fully expanded or hatching 3 5 blastocysts when compared with the buffer injected zygotes (45% versus 17%) (See Figure 1).
Example 2 Assessment of mitochondria) function, mtDNA copy number and mtDNA deletion rates in human - IQ-oocytes of various ages and in human embryos showing preimplantation developmental defects.
Patients with a history of either delayed embryo development (6-cell stage or less at 72 hours post insemination) or persistent embryo fragmentation resulting in only Grade 4 or 5 embryos (presence of cellular fragments filling at least 30% of total embryo volume) will be included in the study. At the time of retrieval, approximately 20% of oocytes are immature and thus unsuitable for fertilization using ICSI. These oocytes will be used in order to determine whether these patients have a maternal predisposition towards abnormal embryonic development that can be attributed to mitochondria. Rates of mitochondria dysfunction will be compared to immature oocytes obtained from patients with known history of normal embryo development. In addition, fragmented embryos, unsuitable for transfer, will be analyzed and their mitochondria) status compared between these two groups. The effect of maternal age will also be determined by examining mitochondria) normality in patients aged 25-30 years, 30-35 years and 35 above. The following experiments are proposed.
Al Mitochondria) function: Changes in mitochondria) membrane potential reflect mitochondria) function since energy produced during mitochondria) respiration is stored as an electrochemical gradient across the mitochondria) membrane and is used to drive ATP
production. Disruption of mitochondria) membrane potential is one of the first signs of apoptosis in many somatic cells. Briefly, oocytes and embryos will be incubated with a fluorochrome (DePsipher, R&D
Systems) that allows simultaneous detection of mitochondria with disrupted (non-functional) and maintained mitochondria) potential. Samples will be analyzed using a deconvolution microscope and the amount of fluorescence 2 0 will be recorded using Delta Vision software package (Silicon Graphics).
In dying cells or those with disrupted membrane potential, the dye will remain in its monomeric form in the cytoplasm and the mitochondria will appear green, whereas in healthy cells the dye aggregates in the mitochondria will appear red. Furthermore, this technique can be used to estimate mitochondria) copy number based on the total amount of fluorescence emitted on both channels. The immature (GV
and MI stage) oocytes 2 5 obtained from the ICSI program, unfertilized oocytes from IVF, and spare embryos donated to research will be analyzed.
~l Mitochondria) coRv number: In order to determine whether recurrent embryo fragmentation observed in some patients could be attributed to insufficient mitochondria) copy number within maternal stores, semi-quantitative PCR (Chen et al. 1995 Am J Hum Genet 57, 239-47) will be used 3 0 to estimate approximate mtDNA copy number. After staining and assessment of mitochondria) function, individual oocytes or embryos will be placed in 20 p) of PBS and stored in -70°C. Before PCR, samples will be boiled and 1/10 of the volume of the lysate will be used as a template for the PCR
reaction.
C) mtDN.9 deletions: Although the above studies will determine the viability and abundance of the 3 5 mitochondria, a further assessment can be done using PCR to semi-quantitatively assess mtDNA
deletions in the same population of human oocytes and embryos used above.
Different PCR primer sets, encompassing all regions of the mitochondria) chromosome, have been designed and the proportion of mitochondria with a deletion in any part of the chromosome will be determined using the approach of Zhang et al. (Biochem Biophys Res Commun 1996 Jun 14;223(2):450-5). This method of scanning the whole chromosome with multiple primer sets will circumvent the problems previously observed with very long mtDNA PCR (Kajander et al., Biochem Biophys Res Commun 1999 Jan 19;254(2):507-14). Preliminary results have shown that the 4799 by common deletion can be easily identified. In addition, amplified products will be subcloned and sequenced in order to identify specific deletions that could be associated with activation of PCD.
Expected Outcome. Information about mitochondria) function, mtDNA status and an estimate of mtDNA copy number will be obtained. This will allow comparison of different oocytes and embryos in order to determine whether there might be a predisposition towards mitochondria) dysfunction in some infertile patients. This data will also be analyzed with respect to increased maternal age and confirm previous reports of a higher rate of mtDNA mutations associated with reproductive senescence.
Example 3 Isolation of mitochondria and mouse models of embryo demise The ability of an enriched fraction of mitochondria, isolated from both somatic cells and different types of stem cells, to enhance developmental potential and to suppress apoptosis following injection into oocytes will be assessed. The cells used for these experiments will include marine embryonic stem (ES) cells, marine and human trophectodemial stem (TS) cells, and human or marine 2 0 CD34+/CD38- hematopoetic stem cells and granulosa cells. ES and TS cells will be grown in vitro under standard culture conditions (Hadjantonakis et al. Mech Dev. 1998 Aug;76( I-2):79-90, Tanaka et al. Science. 1998 Dec 11;282(5396):2072-5). The nucleated cells obtained from human umbilical cord blood of healthy donors will be isolated using a Ficoll gradient.
CD34+/CD38- cells will be separated using a cell depletion magnetic column. Equivalent (but adult rather than fetal) cells can also 2 5 be obtained from marine bone marrow of adult animals (Ploemacher et al.
Exp Hematol. 1989 Mar;l7(3):263-6). The somatic cell source will be luteinized granulosa/cumulus cells isolated from follicular fluid during oocyte retrieval for IVF or from ovaries of hormonally primed mice (Trbovich et al. Cell Death Differ. 1998 Jan;S(1):38-49). An enriched mitochondria) fraction can be isolated from all stem cell types and from granulosa cells using the method of Rickwood (barley-Usmer VM., 3 0 Rickwood D, Willson MT. Mitochondria, a Practical Approach, Oxford Washington DC., IRL Press, 1987, pp. 1-16). Briefly, cells are suspended in a sucrose-based buffer and lysed using a glass homogenizer. The nuclei are pelleted and the mitochondria) fraction is further enriched and purified using a continuous Percoll gradient to separate damaged from intact mitochondria and to eliminate most cellular debris. Scanning and transmission electron microscopy will be used to assess the purity 3 5 and morphology of the mitochondria) fraction. The maintenance of membrane mitochondria) potential will be analyzed by DePsipher dye as described above in Example 1, coupled with FACS analysis for rapid calculation of the total number and concentration of both functional and damaged mitochondria present. Only fractions containing greater than 90% functional mitochondria will be used in the subsequent studies.
a Abili ofmitochondria to suppr~ ess fragmentation in FVB strain mouse oocvtes cultured in vitro.
Mature oocytes of FVB strain mice undergo a very high rate (-75%) of spontaneous fragmentation within 48 hours when cultured in vitro (Morita et al. Dev Biol.
1999 Sep 1;213( 1):1-17).
This model will be used to test each mitochondria enriched fraction for its ability to suppress oocyte fragmentation. Ovulated oocytes will be stripped of their cumulus cells and will be injected with mitochondria enriched fraction in a dose response fashion according to the technique of Van Blerkom et al.. (Hum Reprod. 1998 Oct;l3(10):2857-68). It has been estimated that mature oocytes contain about 100,000 mitochondria (Jansen and de Boer, Mol Cell Endocrinol. 1998 Oct 25;145(1-2):81-8).
Between 2000 and 20,000 mitochondria in a volume of 5 to 15 picot will be injected. A control group of oocytes will be left intact or injected with either buffer used for suspension of mitochondria, or with the mitochondria depleted fraction. Damaged mitochondria obtained from the percoll gradient will also be injected to determine possible negative effects of damaged mitochondria on oocyte survival. All oocytes will then be cultured and scored for fragmentation at 24 and 48 hours.
This model will be used to confirm the optimal number and type of mitochondria to inject to protect against fragmentation Expected Outcome: It is expected that mitochondria derived from stem cells will be successful in preventing fragmentation, and will have the benefit of potential replicative ability.
b) Does injection of mitochondria from stem cells into normal mouse zygotes fertilized in vitro provide 2 0 long-lasting protection from cell death?
Increased maternal age and fertilization in vitro combines to result in an apoptosis rate of about 30% in murine zygotes, and to a higher cell death index at the blastocyst stage, compared to zygotes obtained from young mothers fertilized in vivo (about a 2%
fragmentation rate) (Jurisicova et al.. Mol Hum Reprod. 1998 Feb;4(2):139-45). Moreover, analysis of cell death rates in human 2 5 blastocysts demonstrated that approximately 30% of embryos preferentially eliminated the inner cell mass or activated cell death in the majority of cells. To assess if injection of mitochondria can prevent apoptosis in zygotes and also provide protection during the later developmental stages, zygotes from aged mice (ICR strain 44 weeks old) will be injected with an enriched fraction of mitochondria and their development to the blastocyst stage will be observed in vitro. The number of mitochondria to be 3 0 injected will be estimated using the methods set out in the previous experiment, and the concentration will be fine tuned if necessary. At day 4.5, blastocyst cell numbers and cell death rates will be recorded, with particular attention to the inner cell mass.
Further studies will examine the impact of mitochondria) injection on protection from cell death caused by various toxicants as an artificial trigger of apoptosis. In particular, whether 3 5 mitochondria) injection can prevent apoptosis induced by treatment with doxorubicin (Bergeron et al..
1998 Gen. Dev. 12, 1304-1314), hyperglycaemia (Moley et al. Nat Med 1998 Dec;4( 12):1421-4) and DMBA, which have all been shown to activate the cell death pathway during blastocyst formation, will WO 01/30980 CA 02389117 2002-04-26 PC'f/CA00/01283 be investigated. In these experiments, zygotes injected with appropriate mitochondria will be cultured in KSOM medium until they reach the early blastocyst stage, when the experimental treatment will be performed in vitro with either doxorubicin (200nM), glucose (30mM) enriched medium or with DMBA
( 1 pM). Zygotes injected with buffer or with mitochondria-depleted fractions that develop to the blastocyst stage will be used as controls. At 24 hours the toxicant addition, blastocyst cell number and cell death index will be determined as previously described (Jurisicova et al.. 1998, supra).
Expected outcome. Somatic cell mitochondria have been shown to be diluted out by subsequent cell divisions of preimplantation embryos, and are non-detectable by the blastocyst stage (Ebert et a).1989, J Reprod Fertil. Jan; 82(l): I45-9 9). Stem cell mitochondria should behave more like oocyte mitochondria, which have been demonstrated by Van Blerkom et al. (Hum Reprod.
Oct;13( 10):2857-68) to be detectable at least 80 hours after injection into mouse oocytes. If the donor stem-cell mitochondria are replicative and persist to the blastocyst stage, protection from spontaneous apoptosis in vitro, and decreased rates of cell death following toxicant administration should be observed.
c) Assessment of normal development of mice derived from yotes injected with stem-cell mitochondria.
To determine if mitochondria injection may compromise normal development and life span, FVB zygotes will be injected with various stem or somatic cell mitochondria-enriched fractions as described above and transferred into pseudopregnant females. At least 20 progeny in each group will 2 0 be obtained. The offspring will be followed over an 18-month period for detection of any developmental abnormalities, reproductive dysfunction, or reduced life span, that might be attributable to a deleterious effect of donor mitochondria injection on pre and postnatal development. Moreover, since 7S% of oocytes from this strain normally undergo apoptosis in vitro, female offspring will also be assessed for their oocyte fragmentation rate in vitro to determine if the donor mitochondria have 2 5 replicated in the offspring, producing heteroplasmy. All the parameters will be compared with offspring generated from sham injected zygotes.
Another way to determine the replicative ability of donor stem-cell mitochondria is to utilize restriction fragment length polymorphism (RFLP) in mtDNA, as has been reported between strains CS7Bl6/J and NZBBINJ (Jackson laboratories) (Meirelles and Smith, Genetics 1998 Feb;148(2):877-3 0 83). The FVB strain will be examined to determine if it contains mtDNA
RFLP similar to either of the two strains and based on these results, TS or ES cell lines will be derived from the opposite strain.
Mitochondria enriched fraction from these genetically distinct cells will be injected into FVB zygotes.
The replicative potential of injected mitochondria can then be confirmed in the offspring by determining the RFLP status of the isolated mitochondria.
3 5 Expected outcome. The offspring created by donor stem-cell mitochondria) injection should be phenotypically normal, with normal lifespan. These mice may have improved reproductive function, and decreased oocyte apoptosis in vitro, if the donor mitochondria are replicative and capable of creating heteroplasmy. The ability to create heteroplasmy is critical to the success of any future clinical studies aimed at correcting heritable mitochondria) diseases.
Dl No rescue of embryo fragmentation mediated by DNA damaee..
A subset of both male and female gametes contain damaged DNA (Sun et al., Biol Reprod.
1997 Mar;56(3):602-7, Lopes et al.. Fertil Steril 1998 Mar;69(3):528-32).
Results of Twigg et al. (Hum Reprod 1998 Ju1;13(7):1864-71) with ROS-induced sperm DNA damage clearly demonstrated the ability of such sperm to undergo decondensation and pronuclear formation, suggesting that early stages of embryo development may occur even if the paternal DNA is fragmented. It is not desirable to rescue embryos with chromosomal abnormalities. Genetic analysis of the cell death pathway in marine gene cells, suggests that one can prevent apoptosis in the female germ line if the trigger is lack of survival signals, but not if the initiating factor is DNA damage. A model developed by Doerksen and Trasler (Biol Reprod 1996 Nov;55(5):1155-62) will be used in which male mice are treated with 5-azacytidine (5-AZC), a drug that interferes with DNA methylation and induces sperm DNA
damage. Female mice, when mated to these treated males, produce embryos with a high rate of fragmentation and low pregnancy rates secondary to chromosomal damage (Doerksen and Trasler, 1996, supra). In this experiment, male animals will be treated with 5-AZC (4 mglkg for 3 weeks), sperm will be collected from the cauda epididimus and injected together with stem cell mitochondria or buffer into the oocytes of FVB strain mice.
Expected outcome. Failure of mitochondria) injection to protect against embryo fragmentation in this 2 0 model will confirm that human embryos will not be rescued in which the cell death pathway has been activated by DNA damage. In addition, the report of injection of donor oocyte cytoplasmic into the oocytes of 7 patients by Cohen and his colleagues (Lancet 1997 Jul 19;350(9072):186-7) described 2 couples in which no improvement in embryo quality was seen. These 2 couples were the only ones in which the men had severe oligoasthenospermia, which has been shown to be associated with a high 2 5 degree of sperm DNA damage (Sun et al., Biol Reprod 1997 Mar;56(3):602-7;
Lopes et al., Fertil Steril 1998 Mar;69(3):528-32, Hum Reprod 1998 Mar;13(3):703-8). The presence of DNA
fragmentation in the sperm may explain why the injections were unsuccessful in these two cases.
Example 4 Overexpression of Mcl-1 and Bcl-xL in stem cell mitochondria to enhance suppression of cell 3 0 death in mouse and human embryos.
In mouse and human oocytes and embryos, two cell death protectors, Bcl-xL and Mcl-1, both of which localize to mitochondria, are abundantly expressed. Variable levels of maternally stored transcripts have been observed for these two proteins in human oocytes suggesting that variation in these proteins may lead to varying susceptibility to cell death triggers.
3 5 Transfected ES cells that overexpress Bcl-x~ or Mcl-1, driven by a ubiquitous chicken b-actin promoter (pCAX - Hadjantonakis et al.. 1998, supra) will be created.
Transfected lines will be selected based on their resistance to neomycin and will be assessed for protein levels of Mcl-1 or Bcl-x~ within their mitochondria) fraction using western blot analysis. Cytochrome C, another mitochondrial-localized protein, will be used as a loading control in order to show enhanced levels of Bcl-xL and Mcl-1 in mitochondria enriched fractions. Upon establishing increased levels of protein expression on the mitochondria) membranes within these cells, mitochondria will be isolated and used in similar experiments to those described above. Therefore, early embryos can be augmented with more functional mitochondria, but also with mitochondria containing a higher protein content of either Bcl-x~ or Mcl-1.
Expected Outcome. If these transfected mitochondria are superior in suppressing cell death compared to their non-transfected counterparts, the importance of either Bcl-x~ or Mcl-I in the prevention of apoptosis and normal embryo development in this model will be established.
Ezample 5 Injection of mitochondria into human oocytes at the time of ICSI and rescue of fragmented embryos.
Twenty patients who have undergone two cycles of IVF and who produce only very fragmented embryos (Grade 4 or S) or embryos with delayed development (6 cells or less at 72 hours post fertilization), will be recruited for a pilot study. Women must have normal day 3 serum FSH
concentrations (<10 IU/L in our lab) initially, but if the results of preliminary studies appear promising, older women with elevated serum FSH concentrations will be enrolled for the procedure as well.
Ovulation induction will consist of a long GnRH-agonist protocol with various human menopausal 2 0 gonadotropins as previously described (Greenblatt et al., Fertil Steril.
1995 Sep;64(3):557-63). Cycles will be monitored using a combination of transvaginal ultrasound and serum estradiol measurements.
Human chorionic gonadotropin will be administered at 36 h before oocyte retrieval. Oocytes will be collected transvaginally under ultrasound guidance. Following oocyte retrieval, the cumulus cells will be removed by exposing the cumulus corona-oocyte complex to hyaluronidase in modified HTF
2 5 medium. Each oocyte will be assessed for maturity and those with a first polar body present (MII) selected for ICSI. Immature oocytes will be used for determination of mitochondria) function and mtDNA copy number and mutations as described in Example 2. Spermatozoa will be prepared on the day of oocyte retrieval as previously described (Sun et al., Biol Reprod. 1997 Mar;56(3):602-7). The ICSI procedure to be used in this study has been previously described in detail (Casper et al., 1996, 3 0 supra). All microinjection procedures will be carried out on the heated stage of an inverted microscope (magnification x200 or x400). For the microinjections, a morphologically normal, motile sperm will be selected from a spem~/PVP droplet and immobilized. Oocytes from each patient will be divided into two groups. Oocytes in group one will be injected with a single sperm as previously described (Casper et al., 1996, supra). Oocytes in group 2 will be injected with a single sperm aspirated into the injection 3 5 pipette together with between 5,000 and 20,000 intact mitochondria from human umbilical cord blood-derived hematopoetic stem/progenitor cells prepared as described above. The volume for injection including both sperm and mitochondria will be kept to a maximum of 15 picot.
Following injection, oocytes will be transferred into a 100 ~I droplet of HTF medium supplemented with 5% human serum albumin in a plastic 60 x 15 mm petri dish, covered with mineral oil and incubated in a humidified 5%
CO, environment at 37°C. Cultured oocytes will be assessed for the presence of two pronuclei, indicative of normal fertilization at 16-18 h after ICSI. Embryo development and grading according to the method of Veeck (1991; Acta Eur Fertil. 1992 Nov-Dec;23(6):275-88) will be performed daily.
The embryo score (cell number X 1/grade) will be determined for each embryo at 48, and 72 hours, and cell number estimated at 96 and 120 hours. Morphologically normal appearing expanded blastocysts will be transferred at day 5 post-fertilization. If normal embryo development occurs in any of the control injected oocytes, they will be transferred first. The pregnancies obtained by this technique will be followed closely and the patients advised to consider amniocentesis to rule out a gross chromosomal abnormality. Babies bom as a result of this procedure will have their cord blood collected and stored for determination of mitochondrial heteroplasmy if possible (ie. if a mtDNA
mutation is detected in the unfertilized oocytes), and which may be responsible for the embryo fragmentation or delayed development seen initially in these patients. The babies will also be followed with assessment for normal development at birth, and at intervals thereafter for as long as the parents agree.
Expected outcome. Group 1 oocytes should result in embryos with delayed development or which are completely fragmented, consistent with the patient's past history. In group 2 oocytes, injection of an enriched fraction of stem cell mitochondria will allow normal development to the blastocyst stage with 2 0 intrauterine transfer and pregnancy in some patients.
The present invention is not to be limited in scope by the specific embodiments described herein, since such embodiments are intended as but single illustrations of one aspect of the invention and any functionally equivalent embodiments are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent 2 5 to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.
All publications, patents and patent applications referred to herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.
3 0 All publications, patents and patent applications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the methodologies etc. which are reported therein which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
It must be noted that as used herein and in the appended claims, the singular forms "a'°, 3 5 "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a gene" includes a plurality of such genes.
The invention relates to compositions and methods for enhancing the developmental potential of oocytes, zygotes, and preimplantation embryos.
BACKGROUND OF THE INVENTION
With in vitro fertilization (IVF) and other assisted reproductive technologies, about 50% of human embryos undergo a suicide program of active cell death and become fragmented. Some infertility patients produce only fragmented embryos, which appears to be the cause of their failure to conceive or carry a pregnancy to term.
In all mammals, including humans, zygote development and the first cleavage divisions depend upon maternal RNA and protein products accumulated during oogenesis.
Reproductive failure can be attributed to the lack of cleavage in the developing embryo. This phenomenon can be traced to a defect in the composition of the oocyte cytoplasm. Maternal cytoplasmic components are involved in embryonic arrest, because the "2-cell block" in mice can be overcome by transplantation of ooplasm from zygotes of non-arresting strains into the zygotes of arresting strains (Muggleton-Hams et al, Nature. 1982 Sep 30;299 (5882):460-2). Similar oocyte cytoplasm transfer experiments demonstrated improvement in the developmental capacity of immature eggs in mice (Flood et al., 1990). Later, Cohen and colleagues obtained a pregnancy in a patient with a history of consistently fragmented 2 0 embryos by transfer of donor oocyte cytoplasm into the patient's oocytes at the time of intracytoplasmic sperm injection (Cohen et al., Lancet, 1997 Jul 19;350(9072):186-7). More recently, Lanzendorf et al. (Fertil Steril. 1999 Mar;71(3):575-7) demonstrated that frozen-thawed oocyte cytoplasm microinjected into oocytes, improved their developmental competency after fertilization, and resulted in a twin pregnancy in a patient who previously produced only fragmented embryos.
2 5 Nuclear transfer as a means of producing identical individuals (clones) has been successfully performed in several mammalian species including goat, sheep, pig, cattle, and mice. In all of these cases, efficiency of this technique is very low. While development of reconstituted embryos to the blastocyst stage is moderate (~40%, Ogura et al, 2000 Biol. Reprod. 62(6):1579-84, 2000; Mol.
Reprod. Development 57:55-59, 2000), live birth rate is unexpectedly low ( 1-7%, Ogura et al, 2000, 3 0 supra, Polejaeva et al Nature 2000 Sep 7;407(6800):86-90). Moreover, extensive fetal and early neonatal death has previously been reported in offspring obtained by nuclear transfer (Rideout WM
3rd, Wakayama T, Wutz A, Eggan K et al 2000 Nat Genet Feb;24(2):109-10).
Thus, there is a need to enhance the developmental potential of oocytes to improve reproductive technologies including nuclear transfer methods.
The invention relates to a method for enhancing developmental potential of oocytes comprising increasing intracellular levels of replicative mitochondria in the oocytes. In an embodiment _2_ of the invention, the intracellular levels of replicative mitochondria are increased by introducing replicative mitochondria into the oocytes. A method of the invention may additionally comprise fertilizing the oocytes to obtain a zygote with increased intracellular levels of replicative mitochondria.
The invention also relates to a method for enhancing developmental potential of zygotes comprising increasing intracellular levels of replicative mitochondria in the zygotes. In an embodiment of the invention, the intracellular levels of replicative mitochondria are increased by introducing replicative mitochondria into zygotes.
The invention further relates to an oocyte or a zygote with increased intracellular levels of replicative mitochondria obtained from a method of the invention.
In a further aspect the invention relates to a composition comprising replicative mitochondria for enhancing developmental potential of oocytes or zygotes, and for treating and preventing heritable mitochondria) diseases. The composition may comprise cryopreserved mitochondria.
In another aspect, the invention provides a method for fertilizing oocytes comprising removing oocytes from a follicle of an ovary, introducing replicative mitochrondria into the oocytes, and fertilizing the resulting oocytes with spermatozoa.
In a still further aspect the invention provides a method for storing and then enhancing the developmental potential of oocytes comprising cryopreserving immature oocytes, thawing the cryopreserved oocytes, and introducing replicative mitochondria into the oocytes. A method is also contemplated for enhancing the developmental potential of oocytes comprising cryopreserving 2 0 replicative mitochondria, thawing the mitochondria, and introducing the replicative mitochondria into oocytes.
The methods and compositions of the invention improve the quality of the oocytes that are being fertilized and the quality of zygotes, to increase the rate of success in embryo development and ongoing pregnancy. The methods and compositions are particularly useful in enhancing the 2 5 developmental potential of oocytes or zygotes with mitochondria) DNA
mutations or abnormal mitochondria) metabolic activity.
In an aspect, the invention provides a method for improving embryo development after in vitro fertilization or embryo transfer in a female mammal comprising implanting into the female mammal an embryo derived from an ooctye or zygote containing increased intracellular levels of 3 0 replicative mitochondria.
The invention also provides a method for reducing the detrimental effects of mitochondria) DNA mutations (e.g. deletion or missense mutations) in the progeny of an individual affected by such mutations comprising introducing into oocytes or zygotes from the individual replicative mitochondria that does not contain the DNA mutations (i.e. healthy mitochondria). The invention further provides 3 5 an oocyte or a zygote comprising both mitochondria with mitochondria) DNA
mutations, and purified and isolated replicative mitochondria that do not contain the mitochondria) DNA mutations (i.e. healthy mitochondria).
The invention also relates to a method for treating heritable mitochondria) diseases in the progeny of an individual affected by such diseases comprising introducing into oocytes or zygotes from the individual replicative mitochondria comprising mitochondria that does not contain the DNA
mutations (i.e. healthy mitochondria).
In an aspect of the invention, the oocyte is a recipient ooctye in a nuclear transfer method.
Thus, the invention relates to a method for enhaincing developmental potential of recipient oocytes in a nuclear transfer method comprising introducing replicative mitochondria into the recipient oocytes.
The invention also contemplates recipient oocytes comprising replicative mitochondria, and blastocyts, embryos, and non-human animals formed from the nuclear transfer methods of the invention. In conventional nuclear transfer methods, the donor nucleus is placed in an enucleated oocyte obtained from a different individual. Thus, mitochondria in the recipient oocyte have not-co-existed with the donor nucleus. Since mitochondria are always maternally inherited, their replication, transcription, ttanslation, and function does not only depend on mitochondria) DNA, but is tightly intercalated with the nuclear genome that co-exists with the mitochrondria. The invention by introducing replicative mitochondria into recipient oocytes enhances the developmental potential of the recipient oocytes. This is expected to increase the live birth rate in nuclear transfer methods.
In an embodiment, the invention provides a method of cloning a non-human mammalian embryo by nuclear transfer comprising (a) introducing a donor cell nucleus derived from a donor cell of a non-human mammal, and 2 0 replicative mitochondria preferably from the same species as the donor cell, more preferably from the same species and cell type as the donor cell, most preferably from the non-human mammal from which the donor cell nucleus is derived, into an enucleated recipient oocyte of the same species as the donor cell to form a nuclear transfer unit, (b) culturing the nuclear transfer unit to form an embryo.
2 5 The method may further comprise permitting the embryo to develop into a cloned mammal.
Therefore, the invention also provides a method of cloning a non-human mammal by nuclear transfer comprising (a) introducing a donor cell nucleus derived from a donor cell of a non-human mammal, and replicative mitochondria preferably from the same species as the donor cell, more preferably 3 0 from the same species and cell type as the donor cell, most preferably from the non-human mammal from which the donor cell nucleus is derived, into a non-human mammalian enucleated recipient oocyte of the same species as the donor cell to form a nuclear transfer unit, (b) culturing the nuclear transfer unit to form an embryo;
3 5 (c) implanting the embryo into the uterus of a surrogate mother of said species, and (d) permitting the embryo to develop into the cloned mammal.
In yet another embodiment, a method of cloning a non-human mammalian fetus by nuclear transfer is provided comprising the following steps:
(a) introducing a donor cell nucleus from a donor cell of a non-human mammal, and replicative mitochondria preferably from the same species as the donor cell, more preferably from the same species and cell type as the donor cell, most preferably from the non-human mammal from which the donor cell nucleus is derived, into an enucleated recipient oocyte of the same species as the donor cell to form a nuclear transfer unit, (b) culturing the nuclear transfer unit until greater than the 2-cell developmental stage; and (c) transferring the cultured nuclear transfer unit to a host non-human mammal of the same species such that the nuclear transfer unit develops into a fetus.
The method may also comprise developing the fetus into an offspring.
In a further aspect the invention provides a recipient oocyte comprising a perivitelline space and a donor cell nucleus and replicative mitochondria preferably from the same species as the donor cell, more preferably from the same species and cell type as the donor cell, most preferably from the same individual from which the donor cell nucleus is dervied, deposited in the perivitelline space.
Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention 2 0 will become apparent to those skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a bar graph showing the effect of mitochondria injection on preimplantaion embryo development.
DETAILED DESCRIPTION OF THE INVENTION
2 5 The term "oocytes" refers to the gamete from the follicle of a female animal, whether vertebrate or invertebrate. Preferably, the animal is a mammal, and more preferably is a non-human primate, a bovine, equine, porcine, ovine, caprine, buffalo, guinea pig, hamster, rabbit, mice, rat, dog, cat, or a human. Suitable oocytes for use in the invention include immature oocytes, and mature oocytes from ovaries stimulated by administering to the oocyte donor, in vitro or in vivo, a fertility 3 0 agent or fertility enhancing agent (e.g. inhibin, inhibin and activin, clomiphene citrate, human menopausal gonadotropins including FSH, or a mixture of FSH and LH, and/or human chorionic gonadotropins). In some embodiments of the invention, the oocytes are aged (e.g. from humans 40 years +, or from animals past their reproductive prime). The oocytes in some embodiments of the invention contain mitochondrial DNA mutations. Methods for isolating oocytes are known in the art.
3 5 In the nuclear transfer embodiments of the invention oocytes are used as recipient cells (such cells are referred to herein as "recipient oocytes"). The recipient ooctyes are obtained from non-human mammals, in particular domestic, sports, zoo, and pet animals including but not limited to bovine, ovine, porcine, equine, caprine, buffalo, and guinea pigs, rabbits, mice, hamsters, rats, primates, etc.
The term "zygote" refers to a fertilized oocyte prior to the first cleavage division.
The expression "enhancing the developmental potential of oocytes" refers to increasing the quality of the oocyte so that it will be more capable of being fertilized and/or enhancing mitochondria) function or activity in the oocyte for subsequent development and reproduction. Increasing the quality of the oocyte, and thus the fertilized oocyte (e.g. zygote), preferably results in enhanced development of the oocyte into an embryo and its ability to be implanted and form a healthy pregnancy. The expression "enhancing the developmental potential of zygotes" refers to increasing the quality of the zygotes and/or enhancing mitochondria) function or activity in the zygotes for subsequent development and reproduction. Increasing the quality of the zygotes, preferably results in enhanced development of the zygotes into an embryo and their ability to be implanted and form a healthy pregnancy. Quality can be assessed by the appearance of the developing embryo by visual means and by the IVF or nuclear transfer success rate. Criteria to judge quality of the developing embryo by visual means include, for example, their shape, rate of cell division, fragmentation, appearance of cytoplasm, and other means recognized in the art of IVF and nuclear transfer.
"Spermatozoa" refers to male gametes that can be used to fertilize oocytes.
"Heritable mitochondria) diseases" refers to diseases caused by defects in mitochondria) DNA or by defects in nuclear genes that are important to mitochondria) function. Examples of mitochondria) diseases include but are not limited to Kearns-Sayre syndrome, MERRF syndrome 2 0 (Myoclonic Epilepsy with Ragged Red Fibres), MELAS syndrome (Mitochondria) Encephalopathy, Myopathy, Lactic Acidosis and Stroke-like episodes), and Leber's disease (I.
Nonaka, Current Opinion in Neurology and Neurosurgery, 5 ( 1992) 622).
The term "replicative microchondria" refers to a preparation of purified mitochondria that are capable of replicating during embryo development and increasing mitochondria) copy number or 2 5 function. The replicative mitochondria is substantially free of other cytoplasmic components including nuclear DNA, mRNA, proteins, antioxidants, and organelles other than mitochondria. The replicative mitochondria preparations are at least 60% free, preferably 75% free, and most preferably 90% free from other cytoplasmic components. Preferably the replicative mitochondria preparations contain greater than 70%, more preferably greater than 80%, most preferably greater than 90% functional 3 0 mitochondria. A replicative mitochondria preparation typically contains about 2,000 to 20,000 mitochondria in a volume of 5 to 15 picot.
For the non-nuclear-transfer embodiments of the invention, replicative mitochondria are preferably derived from any stem cell (e.g. hematopoietic, embryonic, trophoblastic, primordial germ cells) or from any immortalized cell line (e.g. cancer, or intentionally transformed somatic cells) of any 3 5 species, preferably human. The cells are preferably free of the common mitochondria) deletion mutation found clinically in patients with KSS syndrome (i.e. deleted 4799bp region at tit 8470-13,447;
see Simonnetti et al, 1992) and any other pathologic mitochondria) DNA
mutation. Particular methods for preparing replicative mitochondria are illustrated herein and are described in Darley-Usmer VM., Rickwood D, Willson MT. Mitochondria, a Practical Approach, Oxford Washington DC., IRL Press, 1987, pp. 1-16.
Stem cells used to prepare the replicative mitochondria can be genetically modified by genetic engineering techniques. A transgene may be introduced into the cells via conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, or microinjection. Suitable methods for transforming and transfecting cells can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory textbooks. (See also Nolta et al Blood. 1995 Jul 1;86(1):101-10; and Nolta et al Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2414-9; and Kohn et al Nat Med. 1998 Jul;4(7):775-80.). By way of example, a transgene may be introduced into cells using an appropriate expression vector including but not limited to cosmids, plasmids, or modified viruses (e.g. replication defective retroviruses, adenoviruses and adeno-associated viruses). Transfection is easily and efficiently obtained using standard methods including culturing the cells on a monolayer of virus-producing cells (Van der Putten, Proc Natl Acad Sci U S A. 1985 Sep;82(18):6148-52; Stewart et al. ( 1987) EMBO J. 6:383-388). Examples of genes that may be introduced into the stem cells include genes encoding cell death protectors such as Bcl-xL and McL-1.
Cryoprotective methods can be used to maintain maximum viability of the replicative mitochondria. Cryopreservation can be carried out in a medium containing for example 2 0 dimethylsulphoxide, ethylene glycol, or glycerol or sucrose with 1,2-propanediol, or the mitochondria can be vitrified using cryoprotectants such as ethylene glycol and dimethyl sulphoxide. In an embodiment of the invention, the cryopreservation procedure involves cooling the mitochondria in a cryoprotective solution to an appropriate temperature (e.g. -176°).
Scanning and transmission electron microscopy can be used to assess the purity and 2 5 morphology of a preparation. In addition the preparation can be analyzed for membrane mitochondrial potential and the total number and concentration of functional mitochondria present can be determined in accordance with conventional methods as described herein. Replicative ability of the mitochondria in a preparation can be determined using conventional techniques including restriction fragment polymorphism methods as described herein.
3 0 The present invention generally involves the use of replicative mitochondria to enhance the developmental potential of animal oocytes, especially mammals, including sports, zoo, pet, and farm animals, in particular dogs, cats, cattle, pigs, horses, goats, buffalo, rodents (e.g. mice, rats, guinea pigs), monkeys, sheep, and humans. In the nuclear transfer methods, replicative mitochondria are used to enhance the developmental potential of non-human recipient oocytes.
3 5 A method of the invention involves removing the oocytes from follicles in the ovary. This can be accomplished by conventional methods for example, using the natural cycle, during surgical intervention such as oophorohysterectomy, during hyperstimulation protocols in an IVF program, or _7-by necropsy. Oocyte removal and recovery can be suitably performed using transvaginal ultrasonically guided follicular aspiration.
After oocytes have been isolated, replicative mitochondria are introduced into the oocytes, or the oocytes can be cryopreserved for storage in a gamete or cell bank. If the oocytes are not cryopreserved the oocytes should be treated in accordance with the method of the invention preferably within 48 hours after aspiration. If the oocytes are frozen, they can be thawed when it is desired to use them and treated in accordance with a method of the invention.
Replicative mitochondria may be introduced into the oocytes (or zygotes) by conventional microinjection techniques or by other techniques such as electrofusion of mitochondria contained within liposomes or other suitable means.
After introduction, simultaneously with, or prior to the introduction of the replicative mitochondria, the oocytes are fertilized with suitable spermatozoa from the same species. The fertilization can be carried out by known techniques including sperm injection. Suitable human in vitro fertilization and embryo transfer procedures that can be used include in vitro fertilization (IVF) (Trounson et al. Med J Aust. 1993 Jun 21;158( 12):853-7, Trouson and Leeton, in Edwards and Purdy, eds., Human Conception in Vitro, New York:Academic Press, 1982, Trounson, in Crosignani and Rubin eds., In Vitro Fertilization and Embryo Transfer, p. 315, New York:
Academic Press, 1983);
intracytoplasmic sperm injection (ICSI) (Casper et al., Fertil Steril. 1996 May;65(5):972-6); in vitro fertilization and embryo transfer (IVF-ET)(Quigly et al, Fert. Steril., 38:
678, 1982); gamete 2 0 intrafallopian transfer (GIFT) (Molloy et al, Fertil. Steril. 47: 289, 1987); and pronuclear stage tubal transfer (PROST) (Yovich et al., Fertil. Steril. 45: 851, 1987).
The methods and compositions of the invention can be used to increase the success rate of embryo development. In particular, they can be used to reduce the detrimental effects of mitochondrial DNA mutations (e.g. deletion or missense mutations) or abnormal or deficient mitochondrial function 2 5 in the progeny of an individual affected by such mutations or abnormal or deficient function, by introducing in oocytes or zygotes from the individual replicative mitochondria that comprises healthy mitochondria.
Mitochondrial DNA deletions or mutations usually result in impaired oxidative phosphorylation and clinical pathology related to muscle or neurologic tissues. For example Keams-3 0 Sayre syndrome (KSS) or progressive external ophthalinoplegia is the result of a common 4799 by deletion (Holt et al., Ann Neurol. 1989 Dec;26(6):699-708) and Leber's hereditary optic neuropathy (LHON) is due to a missence mutation in the mtDNA (Wallace et al., Science 242, 1427 (1998)).
Therefore, injecting oocytes from individuals with these conditions with healthy replicative mitochondria, creating heteroplasmy, may prevent the detrimental effect of mtDNA missence or 3 5 deletion mutations in the progeny.
The invention also contemplates improved nuclear transfer methods using replicative mitochondria. Nuclear transfer methods or nuclear transplantation methods are known in the literature _g_ and are described in for example, Campbell et al, Theriogenology, 43:181 (1995); Collas et al, Mol.
Report Dev., 38:264-267 ( 1994); Keefer et al, Biol. Reprod., 50:935-939 ( 1994); Sims et al, Proc. Natl.
Acad. Sci., USA, 90:6143-6147 ( 1993); WO 94/26884; WO 94/24274, WO 90/03432, U.S. Pat. Nos.
4,944,384 and 5,057,420.
Methods for isolation of recipient oocytes suitable for nuclear transfer methods are well known in the art. Generally, the recipeint oocytes are surgically removed from the ovaries or reproductive tract of a mammal, e.g., a bovine. Once the oocytes are isolated they are rinsed and stored in a preparation medium well known to those skilled in the art, for example buffered salt solutions Recipient oocytes must generally be matured in vitro before they may be used as recipient cells for nuclear transfer. This process generally requires collecting immature (prophase I) oocytes from mammalian ovaries, and maturing the oocytes in a maturation medium prior to fertilization or enucleation until the oocyte attains the metaphase II stage. Metaphase II
stage oocytes, which have been matured in vivo, may also be used in nuclear transfer techniques.
Enucleation of the recipient oocytes may be carried out by known methods, such as described in U.S. Pat. No. 4,994,384. For example, metaphase II oocytes may be placed in HECM, optionally containing cytochalasin B, for immediate enucleation, or they may be placed in a suitable medium, (e.g. an embryo culture medium), and then enucleated later, preferably not more than 24 hours later.
Enucleation may be achieved microsurgically using a micropipette to remove the polar body and the adjacent cytoplasm (McGrath and Solter, Science, 220:1300, 1983), or using functional enucleanon 2 0 (see U.S. 5,952,222). The recipient oocytes may be screened to identify those which have been successfully enucleated.
The recipient oocytes may be activated on, or after nuclear transfer using methods known to a person skilled in the art. Suitable methods include culturing at sub-physiological temperatures, applying known activation agents (e.g. penetration by spem~, electrical and chemical shock), increasing 2 5 levels of divalent canons, or reducing phosphorylation of cellular proteins (see U.S. 5, 496,720) .
A nucleus of a donor cell, preferably of the same species as the enucleated oocyte, is introduced into the enucleated recipient oocyte. The donor cell nucleus may be obtained from any mammalian cells. Donor cells may be differentiated mammalian cells derived from mesoderm, endoderm, or ectoderm.. In particular, the donor cell nucleus may be obtained from epithelial cells, 3 0 neural cells, epidermal cells, keratinocytes, hematopoienc cells, melanocytes, chondrocytes, B-lymphocytes, T-lymphocytes, erythrocytes, macrophages, monocytes, fibroblasts, and muscle cells.
Suitable mammalian cells may be obtained from any cell or organ of the body.
The mammalian cells may be obtained from different organs including skin, lung, pancreas, liver, stomach, intestine, heart, reproductive organ, bladder, kidney and urethra.
3 5 The nucleus of the donor cell is preferably membrane-bounded. A donor cell nucleus may consist of an entire blastomere or it may consist of a karyoplast. A
karyoplast is an aspirated cellular subset including a nucleus and a small amount of cytoplasm bounded by a plasma membrane. (See Methods and Success of Nuclear Transplantation in Mammals, A. McLaren, Nature, Volume 109, June 21, 194 for methods for preparing karyoplasts).
Replicative mitochondria is introduced into the enucleated recipient oocyte.
The replicative mitochondria is preferably derived from the same species as the donor cell, more preferably from the same species and cell type as the donor cell, and most preferably from the same individual from which the donor cell nucleus is derived. Methods for preparing replicative mitochondria are described herein.
Donor cells may be propagated, genetically modified, and selected in vitro prior to extracting the nucleus, or the replicative mitochondria.
The nucleus of a donor cell and/or the replicative mitochondria may be introduced into an enucleated recipient oocyte using micromanipulation or micro-surgical techniques known in the art (see McGrath and Softer, supra). For example, the nucleus of a donor cell may be transferred to the enucleated recipient oocyte by depositing an aspirated blastomere or karyoplast under the zona pellucida so that its membrane abutts the plasma membrane of the recipient oocyte. This may be accomplished using a transfer pipette. Similar methods may be used to introduce the replicative mitochondria.
Fusion of the donor nucleus and the enucleated oocyte may be accomplished according to methods known in the art. For example, fusion may be aided or induced with viral agents, chemical agents, or electro-induced. Electrofusion involves providing a pulse of electricity sufficient to cause a transient breakdown of the plasma membrane. (See U.S. 4, 994,384). In some cases (e.g. with small 2 0 donor nuclei) it may be preferable to inject the nucleus directly into the oocyte rather than using electroporation fusion. Such techniques are disclosed in Collas and Barnes, Mol. Reprod. Dev., 38:264-267 (1994).
The clones produced using the nuclear transfer methods as described herein may be cultured either in vivo (e.g. in sheep oviducts) or in vitro (e.g. in suitable culture medium) to the morula or 2 5 blastula stage. The resulting embryos may then be transplanted into the uteri of a suitable animal at a suitable stage of estrus using methods known to those skilled in the art. A
percentage of the transplants will initiate pregnancies in the surrogate animals. The offspring will be genetically identical where the donor cells are from a single embryo or a clone of the embryo.
The following non-limiting examples are illustrative of the present invention:
3 0 Ezample 1 Injection of a mitochondria) fraction obtained from a human myeloid cell line (HL-60) accelerated and/or facilitated preimplantation embryonic development. Murine zygotes were microinjected with either a mitochondria) fraction or a buffer at day 0.5 and further cultured in vitro until day 3.5. Embryos receiving mitochondria were twice as likely to form fully expanded or hatching 3 5 blastocysts when compared with the buffer injected zygotes (45% versus 17%) (See Figure 1).
Example 2 Assessment of mitochondria) function, mtDNA copy number and mtDNA deletion rates in human - IQ-oocytes of various ages and in human embryos showing preimplantation developmental defects.
Patients with a history of either delayed embryo development (6-cell stage or less at 72 hours post insemination) or persistent embryo fragmentation resulting in only Grade 4 or 5 embryos (presence of cellular fragments filling at least 30% of total embryo volume) will be included in the study. At the time of retrieval, approximately 20% of oocytes are immature and thus unsuitable for fertilization using ICSI. These oocytes will be used in order to determine whether these patients have a maternal predisposition towards abnormal embryonic development that can be attributed to mitochondria. Rates of mitochondria dysfunction will be compared to immature oocytes obtained from patients with known history of normal embryo development. In addition, fragmented embryos, unsuitable for transfer, will be analyzed and their mitochondria) status compared between these two groups. The effect of maternal age will also be determined by examining mitochondria) normality in patients aged 25-30 years, 30-35 years and 35 above. The following experiments are proposed.
Al Mitochondria) function: Changes in mitochondria) membrane potential reflect mitochondria) function since energy produced during mitochondria) respiration is stored as an electrochemical gradient across the mitochondria) membrane and is used to drive ATP
production. Disruption of mitochondria) membrane potential is one of the first signs of apoptosis in many somatic cells. Briefly, oocytes and embryos will be incubated with a fluorochrome (DePsipher, R&D
Systems) that allows simultaneous detection of mitochondria with disrupted (non-functional) and maintained mitochondria) potential. Samples will be analyzed using a deconvolution microscope and the amount of fluorescence 2 0 will be recorded using Delta Vision software package (Silicon Graphics).
In dying cells or those with disrupted membrane potential, the dye will remain in its monomeric form in the cytoplasm and the mitochondria will appear green, whereas in healthy cells the dye aggregates in the mitochondria will appear red. Furthermore, this technique can be used to estimate mitochondria) copy number based on the total amount of fluorescence emitted on both channels. The immature (GV
and MI stage) oocytes 2 5 obtained from the ICSI program, unfertilized oocytes from IVF, and spare embryos donated to research will be analyzed.
~l Mitochondria) coRv number: In order to determine whether recurrent embryo fragmentation observed in some patients could be attributed to insufficient mitochondria) copy number within maternal stores, semi-quantitative PCR (Chen et al. 1995 Am J Hum Genet 57, 239-47) will be used 3 0 to estimate approximate mtDNA copy number. After staining and assessment of mitochondria) function, individual oocytes or embryos will be placed in 20 p) of PBS and stored in -70°C. Before PCR, samples will be boiled and 1/10 of the volume of the lysate will be used as a template for the PCR
reaction.
C) mtDN.9 deletions: Although the above studies will determine the viability and abundance of the 3 5 mitochondria, a further assessment can be done using PCR to semi-quantitatively assess mtDNA
deletions in the same population of human oocytes and embryos used above.
Different PCR primer sets, encompassing all regions of the mitochondria) chromosome, have been designed and the proportion of mitochondria with a deletion in any part of the chromosome will be determined using the approach of Zhang et al. (Biochem Biophys Res Commun 1996 Jun 14;223(2):450-5). This method of scanning the whole chromosome with multiple primer sets will circumvent the problems previously observed with very long mtDNA PCR (Kajander et al., Biochem Biophys Res Commun 1999 Jan 19;254(2):507-14). Preliminary results have shown that the 4799 by common deletion can be easily identified. In addition, amplified products will be subcloned and sequenced in order to identify specific deletions that could be associated with activation of PCD.
Expected Outcome. Information about mitochondria) function, mtDNA status and an estimate of mtDNA copy number will be obtained. This will allow comparison of different oocytes and embryos in order to determine whether there might be a predisposition towards mitochondria) dysfunction in some infertile patients. This data will also be analyzed with respect to increased maternal age and confirm previous reports of a higher rate of mtDNA mutations associated with reproductive senescence.
Example 3 Isolation of mitochondria and mouse models of embryo demise The ability of an enriched fraction of mitochondria, isolated from both somatic cells and different types of stem cells, to enhance developmental potential and to suppress apoptosis following injection into oocytes will be assessed. The cells used for these experiments will include marine embryonic stem (ES) cells, marine and human trophectodemial stem (TS) cells, and human or marine 2 0 CD34+/CD38- hematopoetic stem cells and granulosa cells. ES and TS cells will be grown in vitro under standard culture conditions (Hadjantonakis et al. Mech Dev. 1998 Aug;76( I-2):79-90, Tanaka et al. Science. 1998 Dec 11;282(5396):2072-5). The nucleated cells obtained from human umbilical cord blood of healthy donors will be isolated using a Ficoll gradient.
CD34+/CD38- cells will be separated using a cell depletion magnetic column. Equivalent (but adult rather than fetal) cells can also 2 5 be obtained from marine bone marrow of adult animals (Ploemacher et al.
Exp Hematol. 1989 Mar;l7(3):263-6). The somatic cell source will be luteinized granulosa/cumulus cells isolated from follicular fluid during oocyte retrieval for IVF or from ovaries of hormonally primed mice (Trbovich et al. Cell Death Differ. 1998 Jan;S(1):38-49). An enriched mitochondria) fraction can be isolated from all stem cell types and from granulosa cells using the method of Rickwood (barley-Usmer VM., 3 0 Rickwood D, Willson MT. Mitochondria, a Practical Approach, Oxford Washington DC., IRL Press, 1987, pp. 1-16). Briefly, cells are suspended in a sucrose-based buffer and lysed using a glass homogenizer. The nuclei are pelleted and the mitochondria) fraction is further enriched and purified using a continuous Percoll gradient to separate damaged from intact mitochondria and to eliminate most cellular debris. Scanning and transmission electron microscopy will be used to assess the purity 3 5 and morphology of the mitochondria) fraction. The maintenance of membrane mitochondria) potential will be analyzed by DePsipher dye as described above in Example 1, coupled with FACS analysis for rapid calculation of the total number and concentration of both functional and damaged mitochondria present. Only fractions containing greater than 90% functional mitochondria will be used in the subsequent studies.
a Abili ofmitochondria to suppr~ ess fragmentation in FVB strain mouse oocvtes cultured in vitro.
Mature oocytes of FVB strain mice undergo a very high rate (-75%) of spontaneous fragmentation within 48 hours when cultured in vitro (Morita et al. Dev Biol.
1999 Sep 1;213( 1):1-17).
This model will be used to test each mitochondria enriched fraction for its ability to suppress oocyte fragmentation. Ovulated oocytes will be stripped of their cumulus cells and will be injected with mitochondria enriched fraction in a dose response fashion according to the technique of Van Blerkom et al.. (Hum Reprod. 1998 Oct;l3(10):2857-68). It has been estimated that mature oocytes contain about 100,000 mitochondria (Jansen and de Boer, Mol Cell Endocrinol. 1998 Oct 25;145(1-2):81-8).
Between 2000 and 20,000 mitochondria in a volume of 5 to 15 picot will be injected. A control group of oocytes will be left intact or injected with either buffer used for suspension of mitochondria, or with the mitochondria depleted fraction. Damaged mitochondria obtained from the percoll gradient will also be injected to determine possible negative effects of damaged mitochondria on oocyte survival. All oocytes will then be cultured and scored for fragmentation at 24 and 48 hours.
This model will be used to confirm the optimal number and type of mitochondria to inject to protect against fragmentation Expected Outcome: It is expected that mitochondria derived from stem cells will be successful in preventing fragmentation, and will have the benefit of potential replicative ability.
b) Does injection of mitochondria from stem cells into normal mouse zygotes fertilized in vitro provide 2 0 long-lasting protection from cell death?
Increased maternal age and fertilization in vitro combines to result in an apoptosis rate of about 30% in murine zygotes, and to a higher cell death index at the blastocyst stage, compared to zygotes obtained from young mothers fertilized in vivo (about a 2%
fragmentation rate) (Jurisicova et al.. Mol Hum Reprod. 1998 Feb;4(2):139-45). Moreover, analysis of cell death rates in human 2 5 blastocysts demonstrated that approximately 30% of embryos preferentially eliminated the inner cell mass or activated cell death in the majority of cells. To assess if injection of mitochondria can prevent apoptosis in zygotes and also provide protection during the later developmental stages, zygotes from aged mice (ICR strain 44 weeks old) will be injected with an enriched fraction of mitochondria and their development to the blastocyst stage will be observed in vitro. The number of mitochondria to be 3 0 injected will be estimated using the methods set out in the previous experiment, and the concentration will be fine tuned if necessary. At day 4.5, blastocyst cell numbers and cell death rates will be recorded, with particular attention to the inner cell mass.
Further studies will examine the impact of mitochondria) injection on protection from cell death caused by various toxicants as an artificial trigger of apoptosis. In particular, whether 3 5 mitochondria) injection can prevent apoptosis induced by treatment with doxorubicin (Bergeron et al..
1998 Gen. Dev. 12, 1304-1314), hyperglycaemia (Moley et al. Nat Med 1998 Dec;4( 12):1421-4) and DMBA, which have all been shown to activate the cell death pathway during blastocyst formation, will WO 01/30980 CA 02389117 2002-04-26 PC'f/CA00/01283 be investigated. In these experiments, zygotes injected with appropriate mitochondria will be cultured in KSOM medium until they reach the early blastocyst stage, when the experimental treatment will be performed in vitro with either doxorubicin (200nM), glucose (30mM) enriched medium or with DMBA
( 1 pM). Zygotes injected with buffer or with mitochondria-depleted fractions that develop to the blastocyst stage will be used as controls. At 24 hours the toxicant addition, blastocyst cell number and cell death index will be determined as previously described (Jurisicova et al.. 1998, supra).
Expected outcome. Somatic cell mitochondria have been shown to be diluted out by subsequent cell divisions of preimplantation embryos, and are non-detectable by the blastocyst stage (Ebert et a).1989, J Reprod Fertil. Jan; 82(l): I45-9 9). Stem cell mitochondria should behave more like oocyte mitochondria, which have been demonstrated by Van Blerkom et al. (Hum Reprod.
Oct;13( 10):2857-68) to be detectable at least 80 hours after injection into mouse oocytes. If the donor stem-cell mitochondria are replicative and persist to the blastocyst stage, protection from spontaneous apoptosis in vitro, and decreased rates of cell death following toxicant administration should be observed.
c) Assessment of normal development of mice derived from yotes injected with stem-cell mitochondria.
To determine if mitochondria injection may compromise normal development and life span, FVB zygotes will be injected with various stem or somatic cell mitochondria-enriched fractions as described above and transferred into pseudopregnant females. At least 20 progeny in each group will 2 0 be obtained. The offspring will be followed over an 18-month period for detection of any developmental abnormalities, reproductive dysfunction, or reduced life span, that might be attributable to a deleterious effect of donor mitochondria injection on pre and postnatal development. Moreover, since 7S% of oocytes from this strain normally undergo apoptosis in vitro, female offspring will also be assessed for their oocyte fragmentation rate in vitro to determine if the donor mitochondria have 2 5 replicated in the offspring, producing heteroplasmy. All the parameters will be compared with offspring generated from sham injected zygotes.
Another way to determine the replicative ability of donor stem-cell mitochondria is to utilize restriction fragment length polymorphism (RFLP) in mtDNA, as has been reported between strains CS7Bl6/J and NZBBINJ (Jackson laboratories) (Meirelles and Smith, Genetics 1998 Feb;148(2):877-3 0 83). The FVB strain will be examined to determine if it contains mtDNA
RFLP similar to either of the two strains and based on these results, TS or ES cell lines will be derived from the opposite strain.
Mitochondria enriched fraction from these genetically distinct cells will be injected into FVB zygotes.
The replicative potential of injected mitochondria can then be confirmed in the offspring by determining the RFLP status of the isolated mitochondria.
3 5 Expected outcome. The offspring created by donor stem-cell mitochondria) injection should be phenotypically normal, with normal lifespan. These mice may have improved reproductive function, and decreased oocyte apoptosis in vitro, if the donor mitochondria are replicative and capable of creating heteroplasmy. The ability to create heteroplasmy is critical to the success of any future clinical studies aimed at correcting heritable mitochondria) diseases.
Dl No rescue of embryo fragmentation mediated by DNA damaee..
A subset of both male and female gametes contain damaged DNA (Sun et al., Biol Reprod.
1997 Mar;56(3):602-7, Lopes et al.. Fertil Steril 1998 Mar;69(3):528-32).
Results of Twigg et al. (Hum Reprod 1998 Ju1;13(7):1864-71) with ROS-induced sperm DNA damage clearly demonstrated the ability of such sperm to undergo decondensation and pronuclear formation, suggesting that early stages of embryo development may occur even if the paternal DNA is fragmented. It is not desirable to rescue embryos with chromosomal abnormalities. Genetic analysis of the cell death pathway in marine gene cells, suggests that one can prevent apoptosis in the female germ line if the trigger is lack of survival signals, but not if the initiating factor is DNA damage. A model developed by Doerksen and Trasler (Biol Reprod 1996 Nov;55(5):1155-62) will be used in which male mice are treated with 5-azacytidine (5-AZC), a drug that interferes with DNA methylation and induces sperm DNA
damage. Female mice, when mated to these treated males, produce embryos with a high rate of fragmentation and low pregnancy rates secondary to chromosomal damage (Doerksen and Trasler, 1996, supra). In this experiment, male animals will be treated with 5-AZC (4 mglkg for 3 weeks), sperm will be collected from the cauda epididimus and injected together with stem cell mitochondria or buffer into the oocytes of FVB strain mice.
Expected outcome. Failure of mitochondria) injection to protect against embryo fragmentation in this 2 0 model will confirm that human embryos will not be rescued in which the cell death pathway has been activated by DNA damage. In addition, the report of injection of donor oocyte cytoplasmic into the oocytes of 7 patients by Cohen and his colleagues (Lancet 1997 Jul 19;350(9072):186-7) described 2 couples in which no improvement in embryo quality was seen. These 2 couples were the only ones in which the men had severe oligoasthenospermia, which has been shown to be associated with a high 2 5 degree of sperm DNA damage (Sun et al., Biol Reprod 1997 Mar;56(3):602-7;
Lopes et al., Fertil Steril 1998 Mar;69(3):528-32, Hum Reprod 1998 Mar;13(3):703-8). The presence of DNA
fragmentation in the sperm may explain why the injections were unsuccessful in these two cases.
Example 4 Overexpression of Mcl-1 and Bcl-xL in stem cell mitochondria to enhance suppression of cell 3 0 death in mouse and human embryos.
In mouse and human oocytes and embryos, two cell death protectors, Bcl-xL and Mcl-1, both of which localize to mitochondria, are abundantly expressed. Variable levels of maternally stored transcripts have been observed for these two proteins in human oocytes suggesting that variation in these proteins may lead to varying susceptibility to cell death triggers.
3 5 Transfected ES cells that overexpress Bcl-x~ or Mcl-1, driven by a ubiquitous chicken b-actin promoter (pCAX - Hadjantonakis et al.. 1998, supra) will be created.
Transfected lines will be selected based on their resistance to neomycin and will be assessed for protein levels of Mcl-1 or Bcl-x~ within their mitochondria) fraction using western blot analysis. Cytochrome C, another mitochondrial-localized protein, will be used as a loading control in order to show enhanced levels of Bcl-xL and Mcl-1 in mitochondria enriched fractions. Upon establishing increased levels of protein expression on the mitochondria) membranes within these cells, mitochondria will be isolated and used in similar experiments to those described above. Therefore, early embryos can be augmented with more functional mitochondria, but also with mitochondria containing a higher protein content of either Bcl-x~ or Mcl-1.
Expected Outcome. If these transfected mitochondria are superior in suppressing cell death compared to their non-transfected counterparts, the importance of either Bcl-x~ or Mcl-I in the prevention of apoptosis and normal embryo development in this model will be established.
Ezample 5 Injection of mitochondria into human oocytes at the time of ICSI and rescue of fragmented embryos.
Twenty patients who have undergone two cycles of IVF and who produce only very fragmented embryos (Grade 4 or S) or embryos with delayed development (6 cells or less at 72 hours post fertilization), will be recruited for a pilot study. Women must have normal day 3 serum FSH
concentrations (<10 IU/L in our lab) initially, but if the results of preliminary studies appear promising, older women with elevated serum FSH concentrations will be enrolled for the procedure as well.
Ovulation induction will consist of a long GnRH-agonist protocol with various human menopausal 2 0 gonadotropins as previously described (Greenblatt et al., Fertil Steril.
1995 Sep;64(3):557-63). Cycles will be monitored using a combination of transvaginal ultrasound and serum estradiol measurements.
Human chorionic gonadotropin will be administered at 36 h before oocyte retrieval. Oocytes will be collected transvaginally under ultrasound guidance. Following oocyte retrieval, the cumulus cells will be removed by exposing the cumulus corona-oocyte complex to hyaluronidase in modified HTF
2 5 medium. Each oocyte will be assessed for maturity and those with a first polar body present (MII) selected for ICSI. Immature oocytes will be used for determination of mitochondria) function and mtDNA copy number and mutations as described in Example 2. Spermatozoa will be prepared on the day of oocyte retrieval as previously described (Sun et al., Biol Reprod. 1997 Mar;56(3):602-7). The ICSI procedure to be used in this study has been previously described in detail (Casper et al., 1996, 3 0 supra). All microinjection procedures will be carried out on the heated stage of an inverted microscope (magnification x200 or x400). For the microinjections, a morphologically normal, motile sperm will be selected from a spem~/PVP droplet and immobilized. Oocytes from each patient will be divided into two groups. Oocytes in group one will be injected with a single sperm as previously described (Casper et al., 1996, supra). Oocytes in group 2 will be injected with a single sperm aspirated into the injection 3 5 pipette together with between 5,000 and 20,000 intact mitochondria from human umbilical cord blood-derived hematopoetic stem/progenitor cells prepared as described above. The volume for injection including both sperm and mitochondria will be kept to a maximum of 15 picot.
Following injection, oocytes will be transferred into a 100 ~I droplet of HTF medium supplemented with 5% human serum albumin in a plastic 60 x 15 mm petri dish, covered with mineral oil and incubated in a humidified 5%
CO, environment at 37°C. Cultured oocytes will be assessed for the presence of two pronuclei, indicative of normal fertilization at 16-18 h after ICSI. Embryo development and grading according to the method of Veeck (1991; Acta Eur Fertil. 1992 Nov-Dec;23(6):275-88) will be performed daily.
The embryo score (cell number X 1/grade) will be determined for each embryo at 48, and 72 hours, and cell number estimated at 96 and 120 hours. Morphologically normal appearing expanded blastocysts will be transferred at day 5 post-fertilization. If normal embryo development occurs in any of the control injected oocytes, they will be transferred first. The pregnancies obtained by this technique will be followed closely and the patients advised to consider amniocentesis to rule out a gross chromosomal abnormality. Babies bom as a result of this procedure will have their cord blood collected and stored for determination of mitochondrial heteroplasmy if possible (ie. if a mtDNA
mutation is detected in the unfertilized oocytes), and which may be responsible for the embryo fragmentation or delayed development seen initially in these patients. The babies will also be followed with assessment for normal development at birth, and at intervals thereafter for as long as the parents agree.
Expected outcome. Group 1 oocytes should result in embryos with delayed development or which are completely fragmented, consistent with the patient's past history. In group 2 oocytes, injection of an enriched fraction of stem cell mitochondria will allow normal development to the blastocyst stage with 2 0 intrauterine transfer and pregnancy in some patients.
The present invention is not to be limited in scope by the specific embodiments described herein, since such embodiments are intended as but single illustrations of one aspect of the invention and any functionally equivalent embodiments are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent 2 5 to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.
All publications, patents and patent applications referred to herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.
3 0 All publications, patents and patent applications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the methodologies etc. which are reported therein which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
It must be noted that as used herein and in the appended claims, the singular forms "a'°, 3 5 "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a gene" includes a plurality of such genes.
Claims (33)
1. A method for enhancing developmental potential of oocytes or zygotes comprising increasing intracellular levels of replicative mitochondria in oocytes or zygotes.
2. A method as claimed in claim 1 wherein the intracellular levels of replicative mitochondria are increased by introducing replicative mitochondria derived from stem cells or an immortalized cell line.
3. A method as claimed in claim 2 wherein the replicative mitochondria are introduced by microinjection or electrofusion.
4. A method as claimed in claim 2 or 3 wherein the stem cells have been genetically modified.
5. A method as claimed in claim 1, 2 or 3 wherein the replicative mitochondria comprise mitochondrial DNA free of deletions or mutations.
6. A method as claimed in any of the preceding claims wherein the replicative mitochondria are at least 60% free, preferably 75% free, and most preferably 90% free from other cytoplasmic components.
7. A method as claimed in claim 2 wherein the replicative mitochondria derived from the stem cells or immortalized cell line contains about 2,000 to 20,000 mitochondria.
8. A method as claimed in any of the preceding claims wherein the ooctyes or zygotes are from sports, zoo, pet and farm animals.
9. A method as claimed in any of the preceding claims wherein the developmental potential of human ooctyes are enhanced.
10. An oocyte or zygote with increased intracellular levels of mitochondria obtained from a method as claimed in any of the preceding claims.
11. A method as claimed in claim 9 further comprising fertilizing the oocytes to obtain a zygote with increased intracellular levels of replicative mitochondria.
12. A zygote with increased intracellular levels of mitochondria obtained from a method as claimed in claim 11.
13. A composition comprising replicative mitochondria for enhancing developmental potential of oocytes and zygotes.
14. A composition as claimed in claim 13 wherein the replicative mitochondria is derived from stem cells or an immortalized cell line.
15. A composition as claimed in claim 13 wherein the replicative mitochondria is derived from differentiated mammalian cells.
16. A method for reducing the detrimental effects of mitochondria) DNA
mutations in the progeny of an individual affected by such mutations comprising introducing into oocytes or zygotes from the individual replicative mitochondria comprising healthy mitochondria.
mutations in the progeny of an individual affected by such mutations comprising introducing into oocytes or zygotes from the individual replicative mitochondria comprising healthy mitochondria.
17. A method as claimed in claim 16 wherein the replicative mitochondria comprise mitochondria) DNA free of deletions or mutations resulting in impaired oxidative phosphorylation and clinical pathology related to muscle or neurologic tissues.
18. A method for improving embryo development after in vitro fertilization or embryo transfer in a female mammal comprising implanting into the female mammal an embryo derived from an ooctye or zygote containing increased intracellular levels of replicative mitochondria.
19. A method of cloning a non-human mammal by nuclear transfer comprising (a) introducing a donor cell nucleus derived from donor cell of a non-human mammal, and replicative mitochondria preferably from the same species as the donor cell, more preferably from the same species and cell type as the donor cell, most preferably from the same non-human mammal from which the donor cell nucleus is derived, into an enucleated recipient oocyte of the same species as the donor cell to form a nuclear transfer unit, (b) culturing the nuclear transfer unit to provide an embryo;
(c) implanting the embryo into the uterus of a surrogate mother of said species, and (d) permitting the embryo to develop into the cloned mammal.
(c) implanting the embryo into the uterus of a surrogate mother of said species, and (d) permitting the embryo to develop into the cloned mammal.
20. A method to produce viable embryos of a non-human mammal comprising:
(a) introducing a donor cell nucleus derived from a donor cell of a non-human mammal, and replicative preferably from the same species as the donor cell, more preferably from the same species and cell type as the donor cell, most preferably from the same non-human mammal from which the donor cell nucleus is derived, into an enucleated recipient oocyte of the same species as the donor cell to form a nuclear transfer unit, (b) culturing the nuclear transfer unit to provide an embryo.
(a) introducing a donor cell nucleus derived from a donor cell of a non-human mammal, and replicative preferably from the same species as the donor cell, more preferably from the same species and cell type as the donor cell, most preferably from the same non-human mammal from which the donor cell nucleus is derived, into an enucleated recipient oocyte of the same species as the donor cell to form a nuclear transfer unit, (b) culturing the nuclear transfer unit to provide an embryo.
21. A method of cloning a fetus of a non-human mammal by nuclear transfer comprising the following steps:
(a) introducing a donor cell nucleus derived from a donor cell of a non-human mammal, and replicative preferably from the same species as the donor cell, more preferably from the same species and cell type as the donor cell, most preferably from the same non-human mammal from which the donor cell nucleus is derived, into an enucleated recipient oocyte of the same species as the donor cell to form a nuclear transfer unit, (b) culturing the nuclear transfer unit until greater than the 2-cell developmental stage; and (c) transferring the cultured nuclear transfer unit to a host non-human mammal of the same species such that the nuclear transfer unit develops into a fetus.
(a) introducing a donor cell nucleus derived from a donor cell of a non-human mammal, and replicative preferably from the same species as the donor cell, more preferably from the same species and cell type as the donor cell, most preferably from the same non-human mammal from which the donor cell nucleus is derived, into an enucleated recipient oocyte of the same species as the donor cell to form a nuclear transfer unit, (b) culturing the nuclear transfer unit until greater than the 2-cell developmental stage; and (c) transferring the cultured nuclear transfer unit to a host non-human mammal of the same species such that the nuclear transfer unit develops into a fetus.
22. A method as claimed in claim 21, wherein the fetus develops into an offspring.
23. A method as claimed in any one of claims 19 to 22, wherein the donor cell nucleus is from mesoderm, endoderm, or ectoderm.
24. A method as claimed in any one of claims 19 to 23 wherein the non-human mammal is bovine, ovine, porcine, equine, caprine and buffalo.
25. A method as claimed in any one of claims 19 to 24, wherein the donor cell nucleus is from epithelial cells, neural cells, epidermal cells,keratinocytes, hematopoietic cells, melanocytes, chondrocytes, B-lymphocytes, T-lymphocytes, erythrocytes, macrophages, monocytes, fibroblasts, or muscle cells.
26. A method as claimed in any one of claims 19 to 25, wherein the donor cell nucleus is from an organ selected from the group consisting of skin, lung, pancreas, liver, stomach, intestine, heart, reproductive organ, bladder, kidney and urethra.
27. A method as claimed in any one of claims 19 to 26, wherein the enucleated recipient oocyte is matured in vitro or in vivo prior to enucleation.
28. A method as claimed in any one of claims 19 to 27 wherein the enucleated recipient oocyte is a Metaphase II stage oocyte.
29. A method as claimed in any one of claims 19 to 28 wherein the donor nucleus is membrane-bounded
30. A method as claimed in any one of claims 19 to 29 wherein the donor nucleus is a whole blastomere.
31. A method as claimed in any one of claims 19 to 30 wherein the donor nucleus is a karyoplast aspirated from a blastomere.
32. A recipient oocyte comprising a perivitelline space, and a donor cell nucleus and replicative mitochondria deposited in the perivitelline space.
33. A recipient oocyte as claimed in claim 32 wherein the replicative mitochondria is derived from the same species and cell type as the donor cell nucleus or from the same individual from which the donor cell nucleus is derived.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16179799P | 1999-10-27 | 1999-10-27 | |
US60/161,797 | 1999-10-27 | ||
PCT/CA2000/001283 WO2001030980A2 (en) | 1999-10-27 | 2000-10-27 | Methods and compositions for enhancing developmental potential of oocytes and zygotes |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2389117A1 true CA2389117A1 (en) | 2001-05-03 |
Family
ID=22582774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002389117A Abandoned CA2389117A1 (en) | 1999-10-27 | 2000-10-27 | Methods and compositions for enhancing developmental potential of oocytes and zygotes |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1234021A2 (en) |
JP (1) | JP2003512833A (en) |
AU (1) | AU1123301A (en) |
CA (1) | CA2389117A1 (en) |
WO (1) | WO2001030980A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8021876B2 (en) | 2001-11-15 | 2011-09-20 | Children's Medical Center Corporation | Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof |
GB0200804D0 (en) | 2002-01-14 | 2002-03-06 | Univ Birmingham | Cloning methods and other methods of producing cells |
US7955846B2 (en) | 2004-05-17 | 2011-06-07 | The General Hospital Corporation | Compositions comprising female germline stem cells and methods of use thereof |
AU2005252636A1 (en) | 2004-05-17 | 2005-12-22 | The General Hospital Corporation | Compositions comprising female germline stem cells and methods of use thereof |
CA2832336C (en) * | 2011-04-14 | 2016-08-09 | The General Hospital Corporation | Compositions and methods for autologous germline mitochondrial energy transfer |
AU2014202447B2 (en) * | 2011-04-14 | 2015-05-07 | The General Hospital Corporation | Compositions and methods for autologous germline mitochondrial energy transfer |
CA2847292A1 (en) * | 2011-06-29 | 2013-01-03 | The General Hospital Corporation | Compositions and methods for enhancing bioenergetic status in female germ cells |
WO2019113743A1 (en) * | 2017-12-11 | 2019-06-20 | 清华大学 | Genetic modification method |
CN114214270B (en) * | 2021-12-17 | 2023-11-24 | 中国农业科学院北京畜牧兽医研究所 | Method for regulating and controlling developmental capacity of frozen bovine oocytes and application thereof |
-
2000
- 2000-10-27 JP JP2001533963A patent/JP2003512833A/en active Pending
- 2000-10-27 CA CA002389117A patent/CA2389117A1/en not_active Abandoned
- 2000-10-27 AU AU11233/01A patent/AU1123301A/en not_active Abandoned
- 2000-10-27 WO PCT/CA2000/001283 patent/WO2001030980A2/en not_active Application Discontinuation
- 2000-10-27 EP EP00972510A patent/EP1234021A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2003512833A (en) | 2003-04-08 |
AU1123301A (en) | 2001-05-08 |
WO2001030980A3 (en) | 2001-11-29 |
WO2001030980A2 (en) | 2001-05-03 |
EP1234021A2 (en) | 2002-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Galli et al. | Mammalian leukocytes contain all the genetic information necessary for the development of a new individual | |
Wallach et al. | Micromanipulation: its relevance to human in vitro fertilization | |
CA2317494A1 (en) | Cloning using donor nuclei from differentiated fetal and adult cells | |
Lacham-Kaplan et al. | Fertilization of mouse oocytes using somatic cells as male germ cells | |
US20080044392A1 (en) | Isolation of Stem Cell-Like Cells and Use Thereof | |
CA2389117A1 (en) | Methods and compositions for enhancing developmental potential of oocytes and zygotes | |
JP2010520751A (en) | Pig model of psoriasis | |
Rhind et al. | 69 Dolly: a final report | |
Arat et al. | 25 COLD STORAGE OF TISSUES AS SOURCE FOR DONOR CELLS DOES NOT REDUCE THE IN VITRO DEVELOPMENT OF BOVINE EMBRYOS FOLLOWING NUCLEAR TRANSFER | |
Vajta et al. | 75 HIGHLY EFFICIENT AND RELIABLE CHEMICALLY ASSISTED ENUCLEATION METHOD FOR HANDMADE CLONING IN CATTLE AND SWINE | |
Matshikiza et al. | 57 EMBRYO DEVELOPMENT FOLLOWING INTERSPECIES NUCLEAR TRANSFER OF AFRICAN BUFFALO (SYNCERUS CAFFER), BONTEBOK (DAMALISCUS DORCUS DORCUS) AND ELAND (TAUROTRAGUS ORYX) SOMATIC CELLS INTO BOVINE CYTOPLASTS | |
Bartels et al. | 27 Birth of Africa’s first nuclear-transferred animal produced with handmade cloning | |
Begin et al. | 28 PREGNANCIES RESULTED FROM GOAT NT EMBRYOS PRODUCED BY FUSING COUPLETS IN THE PRESENCE OF LECTIN | |
Wani et al. | 78 CHRONOLOGICAL EVENTS OF IN VITRO MATURATION IN CAMEL (CAMELUSDROMEDARIES) OOCYTES | |
Kim et al. | 47 BOVINE OOCYTE CYTOPLASM SUPPORTS NUCLEAR REMODELING BUT NOT REPROGRAMMING OF MURINE FIBROBLASTS | |
DeLegge et al. | 34 Effect of genotype and cell line on the efficiency of live calf production by somatic cell nuclear transfer | |
Behboodi et al. | 29 HEALTH AND REPRODUCTIVE PROFILES OF NUCLEAR TRANSFER GOATS PRODUCING THE MSP1-42 MALARIA ANTIGEN | |
Nel-Themaat et al. | 61 ISOLATION AND CULTURE OF SOMATIC CELLS OBTAINED FROM SEMEN AND MILK OF GULF COAST NATIVE SHEEP | |
BLASTOCYSTS | 238 Theriogeno [ogy | |
Nel-Themaat | Gamete and cell technologies for use in biological resource banking | |
Rho et al. | 70 PRODUCTION OF CLONES BY FIBROBLAST NUCLEAR TRANSFER FROMAN X-AUTOSOME TRANSLOCATION CARRIER COW | |
Landry | Reconstruction of nuclear transfer embryos in goats and cattle [electronic resource] | |
Kim et al. | 48 EFFECT OF INSULIN-LIKE GROWTH FACTOR-1 SUPPLEMENT TO NCSU-23 MEDIUM ON PREIMPLANTATION DEVELOPMENT OF PORCINE EMBRYOS DERIVED FROM IN VITRO FERTILIZATION AND SOMATIC CELL NUCLEAR TRANSFER | |
Nguyen et al. | 62 SPINDLE MORPHOGENESIS AND THE MORPHOLOGY OF CHROMOSOMES IN MOUSE NUCLEAR TRANSFER: AN ABNORMAL START IN CLONING OF MICE | |
Eckardt et al. | 37 DEVELOPMENTAL POTENTIAL OF CLONE CELLS IN MURINE CLONE-FERTILIZED AGGREGATION CHIMERAS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |